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FOREWORD 
 
Over the past two years, Teach na Daoine Family Resource Centre has received many requests 
from concerned residents both within the area of Mullaghmatt/Cortolvin and from outside this 
catchment area for support in dealing with the physical, psychological and social effects of the 
use of “Herbal” products (Synthetic Cannabinoids). 
In the last 12 months alone, our community has lost two of its young people as a direct result of 
“Herbal” use.  In response to this, a series of public meetings and stakeholder consultations were 
held in late 2014 and out of that process Teach na Daoine commissioned this piece of research to 
investigate the extent of the problem.   
It makes stark reading and outlines the challenges ahead for all within this community, and the 
County of Monaghan.  It is very clear that there is a need for collaboration across a wide range of 
agencies if we are to affect change on this issue.  Teach na Daoine will continue to work with 
Community, Voluntary and Statutory agencies locally to assist in the implementation of the 
recommendations contained within this report.  We will also advocate for legislative change to 
address the legal status of these substances. 
Teach na Daoine wishes to extend its thanks to the  HSE, TUSLA Child and Family Agency, and 
Cavan Monaghan Drug Awareness for their engagement and support in compiling this report.  
We also wish to extend our thanks to Dr. Marie Claire Van Hout and Evelyn Hearne who 
compiled the report in a very short time frame.  
Finally, we wish to extend our most sincere thanks to all of the participants who took part in this 
study.  It is our hope that this research will provide valuable insights to assist in the formulation 
of local responses and will consequently make a positive contribution to the lives of young 
people, their families and our communities. 
Go raibh mile maith agat, 
 
Teach na Daoine Family Resource Centre 
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EXECUTIVE SUMMARY 
 
The use of psychoactive products containing one or more synthetic cannabinoids (SCBs) being 
sprayed onto a herbal substrate (dried plant material) remains a serious drug policy and public 
health concern.  For the purposes of this report, these smoking mixtures are referred to as 
‘Herbal’ products, and contain SCBs and potentially other psychoactive additives.   
 
“Herbal” products cannot be sold for human consumption so they are often sold as incense, 
potpourri or plant food to get around the law.  Of concern is that an ever increasing number of 
diverse SCBs are available in ‘‘Herbal’’ products, both specified and non- specified in product 
contents listing.  This diversification is designed for circumvention of legislative controls.   One 
of the main challenges for legislators remains the chemical malleability of SCBs. Chemical 
formulae can be changed if a particular product is banned and a similar substance can be created 
which mimics the banned product. 
 
Availability, internet retail, shiny packaging, advertising of a stronger ‘high’ than cannabis, 
affordability, a lack of clarity on legal status and difficulty in detection in standard urine 
toxicology tests have fuelled the rise of popularity and use of ‘‘Herbal’’ products.   Users appear 
to be young adults and adolescents, with males appearing more than twice as likely to use 
‘‘Herbal’’.   
 
“Herbal” products are generally smoked in cigarette papers with tobacco or via a water 
pipe/bong or ingested orally as an infusion.  Desired effects for users centre on a sense of elation 
and well-being, an altered perception of reality and empathy but the effects vary in onset and 
duration of action.   
 
Negative consequences of use reported in this study and others include disturbances in 
neurological, cardiovascular and gastrointestinal function, cognitive impairment, and psychiatric 
consequences that may be permanent and/or potentially fatal.  Over time all users in this study 
described a decrease in functioning characterised by a loss of appetite, breathlessness, cardiac 
conditions requiring medication, skin ablations, tooth decay, lethargy, apathy, tremors and 
insomnia, which were exacerbated when attempting to cut back on use, and resulted in general 
neglect of personal hygiene. Difficulties in eating were most common. 
 
Development of dependence in the form of drug tolerance over time, persistence of drug craving, 
a continuous urge to consume despite adverse consequences, scarce attention to other interests 
or duties and clear withdrawal symptoms are well documented.    
 
Because such limited knowledge around the exact chemical composition and toxicology of 
ingredients in ‘‘Herbal’’ products is available, concerns centre on the lack of research on 
pharmacology, toxicology and health consequences in humans, and appropriate medical 
approaches for treatment of acute intoxication.  
 
Supportive and symptomatic treatments such as lorazepam, naltrexone or antipsychotics may be 
efficacious, however further research is required in order for these treatment approaches to be 
widely adopted.  To date, there are no specific antidotes for the consequences of ‘Herbal’ use 
which presents serious issues for those seeking help and for clinicians.  
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LEGISLATIVE AND COMMUNITY CONTEXT 
 
In the Republic of Ireland, the primary legislation controlling drugs are the Misuse of Drugs Act 
1977 and the Misuse of Drugs Act, 1984. These are further amended by the Criminal Justice Act 
1999, the Criminal Justice Act 2006 and the Criminal Justice Act 2007. The Misuse of Drugs 
Regulations 1988 (SI 328 of 1988) (as amended) lists the various substances to which existing 
legislation applies and has two primary purposes which establishes a system of control over 
certain drugs to protect the public from dangerous or potentially dangerous and harmful 
substances and also to facilitate safe use of certain controlled drug substances which, although 
harmful if misused, have medical and therapeutic value.  
 
Under this legislation, unless expressly permitted to do so, it is illegal to possess, supply, 
manufacture, import or export a controlled substance. Controlled substances are substances 
which affect the central nervous system by producing a mind altering effect (for example 
stimulation, depression, hallucinations), and which are either known to be or have the potential 
to be dangerous or harmful to human health, including their liability for misuse or causing social 
harm. Many of these substances have abuse and addiction potential, both physically and 
psychologically.  
 
The control of substances under the Misuse of Drugs Act occurs in cooperation, engagement and 
compliance with international coordinating frameworks such as the United Nations conventions 
which provide the international legal framework for addressing the illicit drugs phenomenon. 
These conventions aim to protect the health of people from inappropriate use of controlled 
drugs and to ensure that the use of controlled drugs is restricted to medical and scientific 
purposes. Substances are scheduled in accordance with Ireland’s obligations under these 
international conventions. Ireland has extended the scope of control to include a wider range of 
substances in the Criminal Justice (Psychoactive Substances) Act 2010 which applies to 
substances not specifically proscribed under the Misuse of Drugs Acts, but which have 
psychoactive effects by making it an offence to sell, import, export or advertise such 
psychoactive substances. This Act aims to prevent misuse of harmful psychoactive substances. 
Many head shop products became illegal in Ireland on 23 August 2010 when the new Criminal 
Justice (Psychoactive Substances) Act 2010 was passed. 
 
The Misuse of Drugs (Amendment) Act 2015, an emergency piece of legislation, was enacted 
following a Court of Criminal Appeal ruling that legislation banning the possession of more than 
100 drugs (including certain psychoactive substances) was unconstitutional. The 2015 Act 
provides that each statutory instrument set out in Schedule 2 of the Act will have statutory effect 
as if it were an Act of the Oireachtas.  This legislative amendment provides that substances 
which were controlled before the court judgment by means of Government order be added to 
the Schedule of the 1977 Act, protecting the legal framework in Ireland by re-controlling 
substances assessed as meriting such control.  
 
Studies on designer psychoactive drugs in the Republic of Ireland to date have largely centred on 
the pre and post legislative detection of psychoactive substance, and use of the popular synthetic 
cathinone drug mephedrone.  This study is the first of its kind in Ireland.  
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‘‘Herbal’’ use has emerged as a major concern for residents and families in the Mullaghmatt area 
following the deaths of a number of young people as a result of their use.  Teach na nDaoine 
Family Resource Centre (FRC) funded by TUSLA Child and Family Agency commissioned this 
research study to obtain clarity on the issue and to assist with the formulation of a response. 
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RESEARCH METHODS 
 
Aims and Objectives 
The aims and objectives of the study were to gain an understanding of individual and collective 
experiences of ‘‘Herbal’’ product use; pathways to misuse or dependence; how dependence is 
reinforced and maintained; recommendations for improved targeting of community drug 
campaigns and harm reduction and, finally, recommendations for future service development 
and drug monitoring in the area.  
 
Design  
Eight stakeholders and one parent were interviewed and represented the perspectives of family, 
drug and community support, mental health, addiction, primary care and council services and 
law enforcement.    
 
A community focus group consisting of 10 participants representing parents, members of the 
community, youth and community workers was facilitated.  
 
Three male (aged 17-38 years) and three female (20-42 years) users of ‘herbal’ were 
interviewed. Five dependent (and current) users of ‘‘Herbal’’ and one dependent (and 
currently abstinent) user (female) took part in in-depth interviews.  User participants 
completed the Severity of Dependence Screener (SDS) (Gossop et al., 1995) which is a 5-item 
questionnaire, with scores of over 7 indicating dependence.  
 
Analysis 
The in depth interviews and focus group captured illustrative data pertaining to choices and 
decision making to use ‘‘Herbal’’ products, experience of sporadic and continued use, reinforcers 
for use, perceptions of risk and abuse potential, harm reduction practices, use of other drugs or 
medicines, adverse health and social consequences, favoured route of administration, and 
perspectives on treatment referral, uptake and outcomes. The data was analysed using thematic 
analysis which located and identified recurrent explicit themes of experiences of ‘‘Herbal’’.   
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FINDINGS 
 
‘Herbal’ products as an Emerging Trend 
 Awareness of the current issue was characterized by rising reports of drug use within 
the community and displacement away from alcohol use. 
 Difficulties estimating prevalence and profiles of users stemmed from widespread 
availability within local communities and other sourcing routes i.e. internet, cross-
border drug tourism, and the hidden nature of use in private homes.  
 Clustering or pockets of “Herbal” use appeared related to availability and social 
networks of users, contained among individuals living in more marginalized and 
deprived areas, and filtering into more mainstream communities. 
 
Profile of users 
 All user participants scored over 7 in the Severity of Dependence (SDS) indicating all 
users interviewed were dependent on “Herbal”.   
 All user participants were unemployed.   
 Three user participants were educated to Junior cert level, two were educated to 
Primary level, and one educated to Leaving cert level. 
 All user participants were single.  Three had children. 
 
Legal status and availability of ‘Herbal’ 
 A lack of clarity regarding legal status was observed by stakeholders and community 
members as confounding efforts to control use.  Existing legislation around psychoactive 
properties in SCB’s were observed to create significant law enforcement difficulties.   
 User participants described cross border travel, so called drug tourism, where they could 
easily purchase “Herbal” products sold as incense in joke shops. 
 User comments centred on the initial affordable price, between 15 to 20 Euro per 1 gram 
bag.  User participants described spending between 60 and 200 Euro per week on 
“Herbal” products for personal use, with amounts spent increasing over time in response 
to compulsive use. 
 
Awareness of harm and Consumption of ‘Herbal’  
 User awareness around the dangers of smoking “Herbal” products was low, and relied on 
personal experience (often too late), peer user networks, and project staff dissemination. 
 All users described exclusive use of “Herbal” and did not consume any other illicit drugs 
or alcohol.  Users reported an incompatibility of “Herbal” products with alcohol.  Alcohol 
consumption was generally low as a result. 
 
Trajectories of use, dependence and withdrawal 
 Users described how the perceived effect changes over time, from pleasure to tolerance, 
and experiences of unpleasant withdrawals.  Users became aware of the fast progression 
toward regular and dependent use when it was too late.   
 Acute physical withdrawal symptoms were reported to include chest pains, chest 
pressure, tachycardia and palpitations, lower extremity pain and spasms, nausea, 
sweating and vomiting.   
8 
 
 Stakeholders reported psychological symptoms such as anxiety, agitation, anger, 
paranoia, self-harm, psychosis, and suicidal thoughts during withdrawal periods.  These 
were corroborated by users and parents interviewed.  
 
Negative consequences of use 
 Over time all users described a decrease in functioning characterised by a loss of 
appetite, breathlessness, cardiac conditions requiring medication, skin ablations, tooth 
decay, lethargy, apathy, tremors and insomnia, which were exacerbated when 
attempting to cut back on use, and resulted in general neglect of personal hygiene,. 
Difficulties in eating were most common. 
 Users also expressed concern about cognitive impairment, ability to concentrate and 
short term memory loss.  Stakeholders were aware of this impairment. 
 
Intentions to Stop and Help-seeking Attempts 
 All user participants described intentions to stop using, and how unpleasant physical and 
mental withdrawal symptoms inhibited achieving abstinence.  The fear of stopping use 
was also grounded in youth psychotic behaviours, suicidal ideation and suicide attempts 
when in withdrawal. 
 Efforts to cease use and successfully self-detoxify are hampered by widespread 
availability.  Users commented that if they were incarcerated, they would be able to stop 
using.  Users also reported previous unsuccessful attempts of using other substances i.e. 
alcohol and cannabis to assist with withdrawals. 
 
Stakeholder and Community Experiences and Observations 
 Services and community members appeared aware of current demands for crisis help-
seeking behaviours and expressed concern about long term impacts on services and 
associated impacts on the community. 
 During the last 12 months, mental health, psychiatry and community service uptake by 
SCB users in crisis has reportedly increased.   
 Frustrations were expressed regarding the perceived “dis-ownership of addiction and 
drug related issues” and the lack of a formulated health service response.   
 Concerns were expressed regarding the uptake of users in crisis into mental health 
services, because psychotic symptoms are deemed secondary to drug misuse and not 
due to an underlying mental health disorder, compounding difficulties in securing 
treatment for the young person.  
 
Responses and a Way forward 
 An integrated, all-inclusive approach, characterized by community empowerment and 
inter-agency collaboration were viewed as important steps forward.  Stakeholder 
comments centred on the need for enhanced awareness of the issue, including GP 
practices, and expedited pathways toward treatment and counselling. 
 Users and community members expressed a desire for the provision of residential 
detoxification in the region with sufficient length of step down care.   
 Enhanced support with trained drug counsellors, clear service pathways and the need 
for youth specific and expedited routes to treatment when the young person indicates a 
desire to stop are required. 
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RECOMMENDATIONS 
The following key policy and practice recommendations were generated; 
 
Policy 
1. Based on current research findings of the harmful nature of “Herbal” products, request 
clarification from the Minister with responsibility for Drugs on current Legal Status with 
a view to disseminating locally to facilitate arrests and prosecutions under recently 
amended Misuse of Drugs Act 1977-2015.  Advocate for a further review of legislation on 
harmful psychoactive substances if required. 
2. Review current cross-border policing approaches to address “Cross Border Drug 
Tourism” in the area.   
3. Review Mental Health policies regarding addiction and access criteria to services when 
psychotic symptoms are deemed ‘secondary to substance misuse’. 
 
Trend Surveillance, Early Warning and Law Enforcement 
4. Establish an expert group and an early warning system regarding Novel Psychoactive 
Substances, locally, nationally and at an EU level to reduce delays in amendments to 
legislation if/when required. 
5. Increase localised monitoring and surveillance of user trends, as it relates to existing 
products, new products, dealer networks and internet sourcing. 
6. Continue to develop CCTV surveillance in local areas to include the monitoring of 
cameras in local Garda Station. 
 
Education and Prevention 
7. Consult with Primary and Secondary schools locally to establish what supports are 
required to deliver SPHE and/or drug education programs to include Novel Psychoactive 
Substances, synthetic cannabinoid’s and/or emerging trends.  
8. Design and implement harm reduction activity presenting information on products, 
contents, dangers of use, overdose prevention and management, and detoxification 
referral for users, and for families in high risk communities. Incorporate Traveller 
specific elements. 
 
Training  
9. Conduct training needs analysis for front line staff (i.e. TUSLA, Primary Care, GP, Gardai 
etc.) to establish current levels of drugs education, brief intervention skills, 
ASIST/SafeTalk and referral pathways to identify gaps in existing knowledge and skills.   
10. Consult with agencies (i.e. Monaghan ETB, NE-RDATF) to deliver Community Addiction 
courses that work to reduce stigma associated with addiction. 
11. Consult with agencies regarding addiction specific training and employment initiatives 
i.e. DSP Drug specific C.E. Schemes. 
 
Clinical Responses 
12. Review current protocol surrounding pharmacological intervention for withdrawal 
symptoms associated with SCB presentations to ensure evidence based responses. 
13. Develop interagency shared care planning for crisis presentations at Accident and 
Emergency and health services, with expedited access, adequate follow-up and supports 
on discharge. 
 
10 
 
Youth Specific Responses 
14. Provide additional resources to develop youth specific addiction responses, including 
age appropriate in-patient detoxification and step-down facilities, adolescent counselling 
service and assertive outreach worker to identify and deliver early intervention 
initiatives. 
15. Increase local sports partnership activity in areas where youth leisure boredom is high. 
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CONCLUSION 
 
This research highlights the concerning rapid development of tolerance, habit forming regular 
use and experience of acute withdrawal symptoms in users and related negative impact on 
families and communities.  
 
The study whilst localised and small-scale, highlights the need for further development of 
clinical awareness and appropriate responses, alongside expedited inter-agency service 
pathways for drug counselling, crisis support, medical treatment and detoxification intervention 
for young users and their families. Users seeking help and patients on admittance need to be 
monitored for withdrawal and symptoms rapidly managed.  
 
Community efforts, via Teach na Daoine Family Resource Centre, to provide family support and 
education, schools education, harm reduction and information on available care pathways are 
vital in the early identification of trends in use, misuse and dependence, and for the support of 
individuals requiring help.  However more resources, expertise and cooperation are required for 
positive outcomes to be realised. 
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Chapter One: Synthetic Cannabinoids (SCBs) 
 
Introduction 
 
The recent phenomenon of use of commercially available psychoactive products containing one 
or more synthetic cannabinoids (hereafter referred to as ‘SCBs’) sprayed onto a herbal substrate 
(dried plant material) known as herbal smoking mixtures remains a serious drug policy and 
public health concern (Vardakou et al., 2010; Fattore and Fratta, 2011; Loeffler et al., 2012; 
McGuinness and Newell, 2012; Gunderson et al., 2012; Ashton, 2012; Seely et al., 2012a; 
Castellanos and Thornton, 2012; Bhatty and Wu, 2013; Harris and Brown, 2013; Spaderna et al., 
2013; Brents and Prather, 2014). Collectively known as ‘K2 or ‘Herbal’ products’, these emerging 
drugs of abuse contain SCBs (Tuv et al., 2012; Rosenbaum et al., 2012; Bretteville-Jensen et al., 
2013; Fantegrossi et al., 2014; Baumann et al., 2014; Soussan and Kjellgren, 2014).  ‘‘Herbal’’ 
products are generally smoked in cigarette papers or via a water pipe (Deluca et al., 2009), 
sometimes with cannabis, via inhalation of burning mixtures, or orally as infusion.  Powdered 
variants are also available (Kikura-Hanajiri et al., 2011). An ever increasing number of diverse 
SCBs are available in ‘‘Herbal’’ products, specified and non- specified in product packaging and 
ultimately designed for circumvention of legislative controls (Lindigkeit et al., 2009; Vandrey et 
al., 2012).   
 
The occurrence of use of SCBs was recognised in Europe as early as 2004 when sold as ‘legal 
highs’ or ‘herbal highs’ over the internet and in head shops (Bryner 2010; Deluca et al. 2009; 
Griffith et al., 2010; Zawilska, 2011; Ashton, 2012; Seely et al., 2012a). Some reports suggest 
SCBs may have originally been manufactured in China (European Monitoring Centre for Drugs 
and Drug Addiction, 2009; Jack, 2009).  Early surveillance and monitoring of trends in SCBs 
occurred in Europe via the EMCDDA REITOX Early Warning System involving the 27 member 
states, and the Psychonaut Project (Schifano et al., 2006; Mustata et al., 2009).  Synthetic 
cannabinoid components were detected in products in 2008 (Deluca et al., 2009; Schifiano et al., 
2009), and traded in the global drug market (Griffith et al., 2010). In 2013, SCBs detected in the 
Early Warning System had increased from 9 in 2009, 11 in 2010, 23 in 2011, 30 in 2012 and 29 
in 2013, with a total of 102 SCBs notified to the EMCDDA by December 2013. By March 2013, 
this increased by another 5 SCBs. Seizures of SCB bulk powders also increased during this time, 
with manufacture of SCB products occurring in Europe (Choi et al., 2013; Ogata et al., 2013).  
Trends in emergent use and retail of SCBs displaced outside of Europe, including the US, 
Australia, New Zealand, Japan, Ukraine, Russia and Taiwan (McLachlan, 2009; Scalzo, 2010; 
Grigoryev et al., 2011a:b; Fattore and Fratta, 2011; Seely et al., 2011; Ashton, 2012).  European 
nations legislated to control SCBs in 2009 (EMCDDA, 2009), with other nations (USA, Australia) 
following suit (Dargan et al. 2011; Kikura-Hanajiri et al., 2011). The following countries 
currently control ‘‘Herbal’’ and/or other SCBs: Austria, Denmark, Estonia, France, Germany, 
Ireland, Italy, Latvia, Lithuania, Luxembourg, Poland, Romania, Sweden and UK (see 
www.emcdda.europa.eu) and with other Member States considering appropriate measures 
(accessed May 13th 2015).  
 
Synthetic Cannabinoids in ‘‘Herbal’’ products 
 
‘‘Herbal’’ products generally contain 3g of plant material which is purposefully laced with SCBs 
(Zuba et al., 2011; Kjellgren et al., 2013).  SCBs are sprayed onto plant material, and 
subsequently dried, crushed and packaged as powdered, loose leaf or pre rolled ‘‘Herbal’’ 
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products (Verster, 2010; Kikura-Hanajiri et al., 2011; Musah et al. 2012a:b; Soussan and 
Kjellgren, 2014). 
 
Synthetic cannabinoid compounds include the; 
1) JWH compounds synthesised by John W Huffman in the 1980s, with JWH-018 most 
characterised to date,  
2) the CP compounds, a cyclohexylphenol series synthesized by Pfizer in the 1970s, with CP-
47,497 and its modified version CP-47,497-C8 most characterised to date,  
3) the HU-compounds, synthesized in the 1960s at the Hebrew University and,  
4) the benzoylindoles, AM-694 and RCS-4  
(Huffman et al., 2008; EMCDDA, 2009; Lindigkeit et al., 2009; Uchiyama et al., 2009, 2010, 
2011a:b; United States Drug Enforcement Administration, 2009; Hudson et al., 2010; Nakajima 
et al., 2011; Fattore and Fratta, 2011).   
 
These SCBS, such as JWH-018, JWH-073 and CP-47,497, bind and activate the cannabinoid 
receptors CB1R and CB2R with exceptional potency and efficacy (Gunderson et al., 2012; Seely 
et al., 2012b; Brents and Prather, 2014).   
 
SCBs consist of seven major structural groups:  
 
(1) naphthoylindoles (JWH-018, JWH-019, JWH-398, JWH-167, JWH-250, JWH-253, JWH-387  
and JWH-073),  
(2) naphthylmethylindoles,  
(3) naphthoylpyrroles,  
(4) naphthylmethylindenes,  
(5) phenylacetylindoles (JWH-250),  
(6) cyclohexylphenols (CP47,497 and homologues of CP 47,497), and  
(7) classical cannabinoids (HU-210, HU-2011)  
(Thakur et al., 2005; Dowling and Regan, 2011; Pierre, 2011; Spaderna et al., 2013)   
 
 
The first generation of ‘Herbal’ contained CP-47,497-C8, JWH-018, and JWH-073, which on 
legislative controls were replaced by structurally similar and pharmacologically active 
compounds (Dargan et al., 2011; Kikura-Hanajiri et al., 2011; Lindigkeit et al., 2009). Products 
are constantly innovating, with new generation designer cannabinoids emerging such as the 
aminoalkylindole JWH-073 (Auwärter et al., 2009; Lindigkeit et al., 2009), the hexyl homolog 
JWH-019 (Dresen et al., 2011), and more recent aminoalkylindoles, JWH-250 (Westphal et al., 
2010) and JWH-398 (Hudson et al., 2010). More than ten JWH have been detected in herbal 
mixtures (Zuba et al., 2011; Uchiyama et al., 2009:2010; Vardakou et al., 2010; Wells and Ott, 
2011; Hudson et al., 2010; Dresen et al., 2010).  During 2010, other market entries included 
JWH-015 (in “Topaz” ), a methyl derivative of JWH-073 (1-butyl-3-(1-(4-
methyl)naphthoyl)indole), a methyl derivative of JWH-018 called JWH-122 (1-pentyl-3-(4-
methyl-1-naphthoyl)indole) and AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) as the 
first halogenated aminoalkylindole found in an herbal mixture (Ernst et al., 2011). In 2009, the 
potent synthetic cannabinoid agonist HU-210 was detected in ‘Herbal’ products in the UK 
(EMCDDA, 2009).  
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‘‘Herbal’’ Product Retail 
 
‘‘Herbal’’ products are often sold as incense products, meditation potpourris, bath additives, air 
fresheners, incense, fragrance or potpourri (Zuba et al., 2011; Seely et al., 2012a; Fattore and 
Fratta, 2011). Marketing as ‘harmless incense’ and the presence of the herbal substrate have 
fuelled the user perception of safety (EMCDDA, 2009, Seely et al., 2012a, Seely et al., 2011; 
Fattore and Fratta, 2011). A small number of qualitative ‘‘Herbal’ user’ studies have been 
undertaken. Meshack et al., (2013) explored the beliefs and perceived social norms around 
‘‘Herbal’’ use with male SCB users, and similar to the telephone interview conducted by 
Gunderson et al., (2014), reported ease of access, and need for compliance with probation terms 
as driving ‘Herbal’ use.  Participants also assume the product is safe and natural (Every-Palmer, 
2011). ‘‘Herbal’’ products are often labeled stating “not for human consumption” “incense”, or “for 
aromatherapy use only” (Seely et al., 2012a) or “not suitable for under 18s” (Spaderna et al., 
2013).  
 
Retail outlets include the internet, smart1 and headshops2, convenience stores and petrol 
stations (Vandrey et al. 2012), with 3 gram packets relatively low priced, widely available and 
retailing for between 20 and 30 euros (Schifiano et al. 2009; Fattore and Fratta, 2011, Wehrman 
2011; Kikura-Hanajiri et al., 2011, Vandrey et al., 2012). Branding is attractive, with exotic brand 
names and a wide open eye imprint common (Sobolevsky et al., 2010).  Products are marketed 
under different brands denoting potency of expected effect (Auwarter et al. 2009; Chainsaw 
2009).  
 
Product nomenclature is ever diverse and dynamic, with popular distribution names including 
“K2”, “K2 Summit”, “‘Spice,” “‘Spice” Gold,” “‘Spice” Diamond,” “Arctic ‘Spice,” “Silver,” “Aroma,” 
“K2,” “Genie,” “Scene” ,“Dream,” “Yucatan Fire”, “Smoke”, “Sence”, “ChillX”, “Space Truckin”, “Solar 
Flare”, “Moon Rocks”, “Kronic”, “Blue Lotus”, “Algerian Blend”, “Aroma, “Scope”, “Genie”, “Zohai”, 
“Banana Cream Nuke”, “Highdi’s Almdröhner”, “Earth Impact”, “‘Spice” Mojo”, “Gorillaz”, “Skunk”, 
“Galaxy Gold”, and “Red X Dawn” to name a few (EMCDDA, 2009; Fattore and Fratta, 2011; 
Bretteville-Jensen et al., 2013; Kjellgren et al., 2013).   
 
‘‘Herbal’’ Contents and Constituents 
 
Online retailed products have been reported to contain comparable purity to validated 
standards in SCBs (Ginsburg et al., 2012). However, significant variability exists within types and 
amounts of SCBs in ‘‘Herbal’’ products, within batches of products and in packages (EMCDDA, 
2009; Hillebrand et al., 2010). Limited knowledge around exact chemical composition and 
toxicology of ‘Herbal’ ingredients is available (Seely et al., 2012a). Creative chemists continue to 
synthesise novel SCBs circumventing existing legislative templates (King, 2013).  
 
The constituents in ‘Herbal’ have changed over time, possibly due to manufacturer efforts to 
circumvent regulatory controls (Ernst et al., 2012; Rosenbaum et al., 2012).  More recent 
developments (May 15th 2015) include the presence of SCBs in cannabis resin type material (for 
                                                          
1
 Smart shops are shops, prominently found in the Netherlands, which sell psychoactive substances in addition to the drug 
paraphernalia found in head shops. 
2
 A head shop is a retail outlet specializing in paraphernalia used for consumption of cannabis, tobacco, legal highs, legal 
party powders and New Age herbs as counterculture art, magazines, music, clothing, and home décor. 
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example ‘Bang Solid’, ‘Afghan’), and in stimulants, hallucinogens and sedatives, MDMA tablets, 
and E- cigarettes (www.emcdda.europa.eu).   
 
In addition to SCBs in ‘Herbal’ products, other added chemicals and excipients include amides, 
esters, benzodiazepines, psychotropic agents such as ‘Salvia Divinorum’, ‘Kratom’ (Mitragyna 
speciosa) and cannabis, synthetic opioid O-desmethyltramadol and the β2–adrenergic agonist 
clenbuterol (Dresen et al., 2010; Uchiyama et al., 2010; Zuba et al., 2011; Arndt et al., 2011; 
Philipp et al., 2011 a:b:c; Ogata et al., 2013). This blend is particularly dangerous and has caused 
fatalities (Kronstrand et al., 2011). Masking agents of natural origin added to confuse detection 
approaches include tocopherol (vitamin E), eugenol, or fatty acids (Dresen et al., 2010).  
 
Other non-cannabinoid substances detected in ‘‘Herbal’’ products include oleamide (in for 
example ‘Aroma’) (Dresen et al., 2010; Uchiyama et al., 2010; Every-Palmer, 2011); harmine and 
harmaline, (Fortunato et al., 2009:2010); myristicin and asarone (Dresen et al., 2010:2011); 
passion flower (Schneir et al., 2011); benzophenone (HM 40) (Dresen et al., 2010: 2011); beach 
bean (Canavalia maritima or Canavalia rosea); blue lotus (Nelumbo nucifera) and dwarf skullcap 
(Scutellaria nana) (Burley, 2008); white or blue water lily (Nymphaea alba or Nymphaea 
caerulea), Indian Warrior (Pedicularis densiflora), Lion’s Ear (also known as Lion’s Tail or Wild 
Dagga; L. leonurus), Maconha Brava (Zornia latifolia), and Honeyweed or Siberian Motherwort 
(Leonurus sibiricus) (Teske et al., 2010); Marshmallow (Althaea officinalis) and Dog Rose or 
Rosehip (Rosa canina) (Seely et al., 2011). Herbal components are generally listed as between 
0.4–3.0 g of a mixture consisting of several potentially psychoactive plants.  
 
Prevalence of Use and User Profiles  
 
Despite efforts to regulate and raise awareness of abuse potential, use of ‘‘Herbal’’ among 
adolescents and young adults (EMCDDA 2009; Donnelly, 2010; Johnston et al., 2011; Forrester et 
al., 2011; Hoyte et al., 2012; Vandrey et al., 2012; Barratt et al., 2013) has increased in popularity 
over time, alongside the reporting of negative medical, psychiatric and social consequences 
(Benford and Caplan 2011; Van der Veer and Fiday, 2011; Hoyte et al., 2012; McGuinness and 
Newell, 2012; Spaderna et al., 2013).  
 
Internet retail, shiny packaging, advertising and marketing of a promise to provide a stronger 
high than cannabis, availability, affordability, safety and legal perceptions, packaging as incense 
or tea, and difficulty in detection in standard urine toxicology tests have fuelled the rise of 
popularity and use of ‘Herbal’ products (Sopris, 2008;  Schifiano et al., 2009; Vardakou et al., 
2010; Fattore and Fratta, 2011; Every-Palmer, 2011; Johnston et al., 2011, Vandrey et al., 2012; 
Ginsburg et al. 2012; Vandrey et al. 2012; Barratt et al., 2013; Spaderna et al., 2013; Winstock 
and Barratt, 2013; Gunderson et al., 2014). Of note is not only media reporting but the extensive 
knowledge exchange between interested and experienced users on the Internet in fuelling SCB 
innovation and displacement (EMCDDA, 2009; Sumnall et al., 2011; Bretteville-Jensen et al., 
2013). 
 
According to Seely et al., ‘Herbal’ users can be categorised into three groups based on prior drug 
use;  
1) marijuana smokers;  
2) casual users seeking to avoid legal consequences; 
3) naïve drug experimenters.  
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Users appear to be young adults and adolescents, with reviews estimating average user age of 23 
years, with males appearing more than twice as likely to use ‘‘Herbal’’ (Castellanos et al., 2011; 
Forrester et al., 2011; Hu et al., 2011; Vandrey et al., 2012; Hoyte et al., 2012; Barratt et al., 2013; 
Papanti et al., 2013). Clinical case reporting indicates intoxication and adverse medical 
consequences post ‘‘Herbal’’ use in male adolescents, and to a lesser extent, young females 
(Zimmermann et al., 2009; Bryner, 2010; Mir et al., 2011; Schneir et al., 2011; Young et al., 
2011).  
 
Poly substance use is common, with ‘‘Herbal’’ along with cannabis (Barratt et al., 2013; Winstock 
and Barratt, 2013), tobacco, alcohol, hallucinogens, ketamine, prescription opiates, MDMA, 
benzodiazepines, amphetamines, cocaine, and Salvia divinorum (Schifano et al. 2010; Castellanos 
et al., 2011; Hu et al., 2011; Vandrey et al.,2012; Vandrey et al., 2012; Winstock and Barratt, 
2013).   
 
At present data sources around the issue of ‘‘Herbal’’ centre on rising reported use in US youth 
user surveys (NIDA, 2012; Wood 2013).  Surveys in the US, have reported on 11% of 17/18 year 
old high school students using ‘Herbal’ (Vandrey et al., 2012), and 7.4% in 15/16 year olds and 
7.9% in 17/18 year olds (Johnston et al., 2013). Prevalence of ‘‘Herbal’’ use is also reported 
among 8% of US college level students, along with concomitant use of other substances such as 
hookah tobacco, cigarettes and marijuana (Hu et al., 2011). Caviness et al., in 2014 reported on 
common prevalence in past month in young US adults compared to opioids, cocaine or 
hallucinogens, with SCB use significantly associated with male gender, not attending school and 
use of cigarettes, excessive alcohol use, marijuana use (daily and weekly) and other drug abuse.  
 
Low prevalence rates are reported in EU surveys, with lifetime prevalence for adults aged 16-64 
years) at 0.2% in 2010/11 and 0.1% in 2011/12 in the UK (England and Wales) (Smith and 
Flatley, 2011; Office for National Statistics, 2012). In Spain, in 2012 a survey of students aged 14 
to 18 years reported low levels of ‘‘Herbal’’ use, at 1.4%, 1.0% and 0.6% reported for lifetime, 
last year and last month prevalence (Spanish Observatory on Drugs, 2012). In Germany, student 
survey has indicated (15-18 years) of reported lifetime use of 9% in 2009, and 7% in 2011 and 
2012 (Werse et al., 2011: 2012; Bernard et al., 2013).  The Global Drug Survey in 2012 reported 
last year prevalence levels of 3.3% among all UK respondents and 5.0% among regular clubbers 
in the UK (Guardian/Mixmag Survey, 2012). Internet drug studies in Sweden have reported on 
3.6% of students aged 14-15 years, and 6.8% of those aged 16-17 years using ‘‘Herbal’’ 
compounds (CAN, 2013).  
 
Effects of ‘‘Herbal’’ Use 
 
Desired effects for ‘‘Herbal’’ users centre on sense of elation, wellbeing, altered perception of 
reality and empathy, generally within a social context (Frattore and Fratta 2011; Kjellgren et al., 
2013), and vary in onset of effect and duration of action (Schnier et al., 2011). Subjective and 
physiologic effects vary (Schifano et al., 2006; Vardakou et al., 2010). Typical acute psychoactive 
effects of ‘Herbal’ include an energizing, disinhibiting, feeling of well-being, euphoria, calmness, 
relaxation, mild perceptual alterations, increased creativity, and mild memory and attentional 
impairments. Perceptual changes centre on migratory flushing or cooling, peripheral numbness, 
tingling and altered depth perception (Schifano et al., 2009; Benji, 2010). Users report ‘‘Herbal’’ 
as having less appetite-stimulating properties than cannabis (Winstock and Barratt, 2013) 
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perhaps due to its capacity to induce nausea and emesis as well as stimulate appetite (Canning 
et al., 2010; Hermanns-Clausen et al., 2013).  
 
Similar to cannabis, the spectrum of effects can include anxiolysis or anxiety, stimulation or 
sedation, and euphoria or dysphoria.  Psychoactive effects of ‘‘Herbal’’ range from pleasurable 
elation to alterations in cognitive abilities, anxiety, psychosis, altered vision, hallucinations, 
excessive fear and motor impairment (Auwärter et al., 2009; Müller et al., 2010; Vardakou et al., 
2010;Castellanos et al., 2011; Forrester et al., 2011; Gunderson et al., 2012; Papanti et al., 2013).  
 
Side effects include dry or “cotton” mouth, pupillary changes including miosis and mydriasis, 
blurry vision and light sensitivity, reddened conjunctiva, cough, hyperthermia, rhabdomyolysis, 
symptoms suggestive of anticholinergic effects and pulmonary inflammation and injury, tinnitus, 
agitation, hot flushes, burning eyes, sickness, xerostomia mydriasis and tachycardia (Auwärter 
et al., 2009; Teske et al., 2010; Banerji et al. 2010; Canning et al. 2010; Sobolevsky et al. 2010; 
Teske et al. 2010; Forrester et al. 2011; Forrester et al., 2011; Loschner et al. 2011; Schneir et al. 
2011; Simmons et al. 2011a:b; Vandrey et al. 2012; Hermanns-Clausen et al. 2013; Alhadi et al. 
2013). Occasional inappropriate laughter, xerostomia, and nystagmus are described (Auwärter 
et al., 2009; Schneir et al., 2011). Duration of effect is variable and can last several hours 
(Auwarter et al. 2009; Deluca et al., 2009; Benji, 2010; Muller et al. 2010a:b; Canning et al., 2010; 
Schneir et al., 2011; Hoyte et al., 2012; Young et al., 2012; Schneir and Baumbacher, 2012; 
Barratt et al., 2013; Winstock and Barratt, 2013). Residual effects can also last hours (Auwarter 
et al., 2009; Shakes, 2008).  
 
Synthetic cannabinoids, in contrast to phytocannabinoids (for example delta-9-
tetrahydrocannabinl or THC found in cannabis), are high potency, high efficacy cannabinoid 
receptor full agonists (Atwood et al., 2010; Atwood et al., 2011; Huffman and Padgett 2005; 
Huffman et al., 2005a:b; Lindigkeit et al., 2009; Marriott and Huffman, 2008; Vardakou et al., 
2010; Tuv et al., 2012).  
 
Acute effects relating to spectrum and intensity differ between ‘Herbal’ and cannabis (Spaderna 
et al., 2013). It is not known whether these differences relate to differences between synthetic 
and phytocannabinoids or to the non-cannabinoid components present in ‘Herbal’ (Spaderna et 
al., 2013). Despite this, recent surveys indicate that ‘‘Herbal’’ users overwhelmingly favor the 
effects of cannabis to the synthetic variety (Winstock and Barratt, 2013; Arfken et al., 2014). 
Generally SCBs exhibit similar side effects to high dose cannabis, but are potentially more 
harmful (Hermanns-Clausen et al., 2013). Metabolites of some commonly present SCBs in 
‘‘Herbal’’ may have antagonist effects at CB1 receptors, which may account for some of the 
differences between cannabis and ‘‘Herbal’’ (Brents et al., 2012; Brents et al., 2011; 
Chimalakonda et al., 2012). This body of research is of interest given the conflicting user 
experiences of cannabis versus ‘‘Herbal’’, and the marketing of ‘‘Herbal’’ as marijuana substitute 
(Sobolevsky et al., 2010; Sopris, 2008; Tung et al., 2012; Gunderson et al., 2012).  
 
The ever changing composition of ‘‘Herbal’’ and uneven consistency in the diverse range of 
products contributes to experiences of undesirable effects and the risk of accidental overdose 
(Lindigkeit et al., 2009; Uchiyama et al., 2010; Tuv et al., 2012; Seely et al., 2012a).  Of grave 
concern is that ‘Herbal’ and emergent SCB compounds have not been rigorously tested in human 
clinical trials (Auwarter et al., 2009). 
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Side-effects of ‘‘Herbal’’ Use  
 
Use of SCBs is a public health concern given reporting of acute CNS and cardiovascular toxicity 
with severe cardiovascular, gastrointestinal and psychiatric sequelae (Gunderson et al., 2012; 
Brents and Prather, 2014). Concerns centre on dearth of research on pharmacology, toxicology 
and health consequences in humans, and appropriate medical approaches for treatment of acute 
intoxication (Frattore and Fratta, 2011).  
 
Acute psychoactive effects affect neurological function, cardiovascular function, gastrointestinal 
function, anxiety, altered perception, cognitive impairment, and mood (Spaderna et al., 2013) 
with adverse effects centring on agitation, dysphoria, psychosis, bizarre behaviour and anxiety. 
Presence of non-cannabinoid ingredient such as O-desmethyltramadol, and ‘Kratom’ (as in the 
mixture ‘Krypton’) may contribute to fatal outcomes (Kronstrand et al., 2011). 
 
A Swedish study on emergency admissions for acute recreational drug intoxication detected 
SCB’s  (JWH analogues) substituted cathinones (butylone, MDPV, methylone), tryptamines  (4-
HO-MET), plant based substances (mitragynine and psilocin) and conventional illegal drugs and 
with mixtures of new and/or conventional drugs in 44% of cases (Helander et al., 2013). 
Emergency presentations report on patient  agitation, panic attacks, tachycardia, nausea, 
paranoid ideation, and hallucinations (Piggee, 2009; Banerji et al., 2010; Vearrier and 
Osterhoudt, 2010; Bebarta et al., 2012). The emergence of symptoms in patients presenting for 
medical attention are unclear in the hours post consumption, and may commence immediately, 
minutes or hours post use (Sobolevsky et al. 2010; Bebarta et al. 2012).  
 
Severe toxicity following synthetic cannabinoid use is reported in the literature (Lapoint et al., 
2011; Simmons et al., 2011a:b). Significant acute intoxication effects of SCBs, include 
hypertension, emesis (vomiting), agitation/anxiety, seizures, and hypokalemia (low potassium 
levels), halting speech and avoidant eye contact paranoia, spasm, tachycardia, chest pain, 
psychiatric symptoms such as anxiety, paranoia, avoidant eye contact, paranoid and grandiose 
delusions, psychosis and agitation (Green et al., 2003; EMCDDA, 2009; Sobolevsky et al., 2010; 
Every-Palmer, 2010; Benford and Caplan, 2011; Lapoint et al. 2011; Schneir and Baumbacher 
2012; Simmons et al. 2011b; Steve 2011; Tofighi and Lee 2012), and dependency (Hurst et al., 
2011; Forrester et al., 2011; Schneir et al., 2011; Ashton, 2012; Bebarta et al., 2012; Gunderson 
et al., 2012; Hermanns-Clausen et al., 2012; Hoyte et al., 2012; Seely et al., 2012a; McKeever et 
al., 2015).   Agitated delirium lasting for several days has been described (Berry-Caban et al., 
2013). 
 
Physical side-effects of use range from nausea to psychomotor agitation, diaphoresis, and 
palpitations (Zimmermann et al., 2009; Every-Palmer et al., 2010: 2011; Schneir et al., 2011; 
Castellanos et al., 2011).  Gastrointestinal effects include nausea, retching and vomiting, 
cardiovascular effects include elevated heart rate and blood pressure, tachycardia and 
hypertension,  chest pain, and cardiac ischemia (Canning et al., 2010; Schneir et al., 2011; Seely 
et al., 2011; Hoyte et al., 2012), with users presenting with panic symptoms, chest pain, 
arrhythmias or palpitations (Teske et al., 2010; Schneir et al., 2011; Simmons et al., 2011a:b; 
Bebarta et al. 2012; Cohen et al., 2012; Young et al., 2011; Hermanns-Clausen et al., 2013).  
 
Irregularities may persist following the ‘Herbal’ episode, with some clinical suspicion that 
‘Herbal’ may precipitate myocardial infarction and even death (Mir et al., 2011; St. James, 2010). 
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Metabolic effects such as hypokalemia, hyperglycemia, and acidosis, and autonomic effects, such 
as fever and mydriasis are reported (Seely et al., 2011; Simmons et al., 2011a). Neurological 
effects include tremor, ataxia, nystagmus, hypertonicity, hyperflexion, fasciculations, and 
hyperextension (Benji, 2010; Donnelly, 2010; Canning et al. 2010; Forrester et al., 2011; Cohen 
et al., 2012; Schneir et al., 2011).  Chronic use of SCBs can result in serious cognitive 
impairment (Zimmermann et al., 2009).  Common cognitive impairments relate to attention, 
concentration, memory, and operating machinery (Musshoff et al., 2013), and may last longer 
than the intoxication period (Soussan and Kjellgren, 2014). Other clinical case studies point to 
acute kidney damage (Bhanushali et al. 2013), generalised convulsions (Schneir and 
Baumbacher, 2011) and ischemic stroke (Fisher, 2010; Freeman et al., 2013).  
 
Perhaps most concerning are reported psychotic symptoms associated with acute and chronic 
‘‘Herbal’’ use. This contributes to the debate around the cannabinoid hypothesis of psychosis, for 
example that exposure to cannabis and cannabinoid agonists is associated with psychosis 
outcomes through activation of CB1R (Sewell et al., 2010; Radhakrishnan et al., 2012; Spaderna 
et al., 2013).  Concerns are grounded in the linear dose-curve response and youth use of 
‘‘Herbal’’ with exposure to cannabis in adolescence potentially contributing to increased risk of 
psychosis later in life (Radhakrishnan et al., 2012; Sewell et al., 2010). Prevalence of psychotic 
effects remain unclear (Barratt et al., 2013; Vandrey et al., 2012), despite psychotic reactions to 
‘’Herbal’’ often presenting as common reason for the seeking of medical assistance (Forrester et 
al., 2011). Psychotic symptoms associated with ‘‘Herbal’’ include auditory and visual 
hallucinations, perceptual alterations, illusions, paranoia, agitation, aggression, catatonia, 
depersonalization, and dissociation (Spaderna et al., 2013). These symptoms generally last 
several hours, although prolonged and persistent episodes have been reported, and in some 
instances did not remit (Hurst et al. 2011; Van der Veer and Fiday, 2011; Tung et al., 2012; 
Berry-Caban et al. 2013). Users also describe vivid visual changes described as “fractals,” “trails,” 
“flashes of colour,” and “geometric patterns—” hallucinations different from typical endogenous 
psychosis (Spaderna et al., 2013).  
 
Loss of consciousness and confused states, panic attacks, suicidal ideation and suicide attempts 
are reported and contribute to serious concerns (Gay, 2010; Seely et al., 2011; Simmons et al., 
2011; Hurst et al., 2011; Van der Veer and Fiday,  2011; Shanks et al., 2012). It is unclear 
whether ‘‘Herbal’’ precipitates psychosis in users both with and without a history of psychotic 
disorders (Every-Palmer, 2010:2011; Pierre, 2011; Müller et al., 2010; Hurst et al., 2011; Pierre, 
2011). However, we know that long-term ‘‘Herbal’’ users often experience irritability and 
anxiety, and psychotic episodes (Castellanos et al., 2011; Every-Palmer, 2010, 2011; Schneir et 
al., 2011).  
 
‘‘Herbal’’ Dependence  
 
Development of ‘‘Herbal’’ dependence3, drug tolerance over time, persistence of drug craving, 
continuous urge to consume despite adverse consequences, scarce attention to other interests 
or duties and clear withdrawal symptomatologies in the event of protracted high dose use are 
documented (Zimmermann et al., 2009; Vardakou et al., 2010; Frattore and Fratta, 2011).   
 
                                                          
3
 See Appendix for the DSM definition of substance dependence.  
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Long term use infers dependency, with withdrawal symptoms including internal restlessness, 
urge to consume more drugs, shaking, sweating, anorexia and insomnia, memory impairment, 
diaphoresis, feeling emotionally numb and emotional disconnect in users, somatic pain, 
palpitations, insomnia, tachycardia, hypertension, hyperventilation, headache, diarrhea, nausea, 
vomiting, and depressed mood (Zimmermann et al., 2009; Spaderna et al., 2013; Soussan and 
Kjellgren, 2014). Withdrawal reactions mostly resolve within a week (Zimmermann et al. 2009; 
Rominger et al. 2013).   
 
Supportive and symptomatic treatments such as lorazepam or antipsychotics may be efficacious, 
as there are no specific antidotes for the consequences of ‘Herbal’ use (Spaderna et al., 2013). 
Animal models have demonstrated the attenuation of THC's effects by the opioid antagonist 
naltrexone (Justinova et al., 2004), and may offer some potential in the case of SCBs 
(Hammerlsey, 2010). A recent study by Rodgman et al., (2014) indicated usefulness of 
naltrexone in the management of post detoxification cravings from SCBs.  
 
Drug Testing 
 
Continued efforts strive to develop novel analytical methods for detection of SCBs (Beuck et al., 
2011; Grigoryev et al., 2011a:b; Hudson et al., 2010; Hudson and Ramsey, 2011; Moran et al., 
2011). Recent innovations in development of a GC–MS screening procedure which combines 
high chromatographic resolution with the existence of well-established libraries also offer 
promise in detection of psychoactives compounds present in herbal mixtures (Auwärter et al., 
2009; Dresen et al., 2010, 2011). 
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Chapter Two: Legislative and Community Context for the Research 
 
Legislative Controls in the Republic of Ireland and Northern Ireland 
In the Republic of Ireland, the primary legislation controlling drugs are the Misuse of Drugs Act 
1977 and the Misuse of Drugs Act, 1984. These are further amended by the Criminal Justice Act 
1999, the Criminal Justice Act 2006 and the Criminal Justice Act 2007. The Misuse of Drugs 
Regulations 1988 (SI 328 of 1988) (as amended) lists the various substances to which existing 
legislation applies and has two primary purposes which establishes a system of control over 
certain drugs to protect the public from dangerous or potentially dangerous and harmful 
substances and also to facilitate safe use of certain controlled drug substances which, although 
harmful if misused, have medical and therapeutic value. Under this legislation, unless expressly 
permitted to do so, it is illegal to possess, supply, manufacture, import or export a controlled 
substance. Controlled substances are substances which affect the central nervous system by 
producing a mind altering effect (for example stimulation, depression, hallucinations), and 
which are either known to be or have the potential to be dangerous or harmful to human health, 
including their liability for misuse or causing social harm. Many of these substances have abuse 
and addiction potential, both physically and psychologically.  
 
The control of substances under the Misuse of Drugs Act occurs in cooperation, engagement and 
compliance with international coordinating frameworks such as the United Nations conventions 
which provide the international legal framework for addressing the illicit drugs phenomenon. 
These conventions aim to protect the health of people from inappropriate use of controlled 
drugs and to ensure that the use of controlled drugs is restricted to medical and scientific 
purposes. Substances are scheduled in accordance with Ireland’s obligations under these 
international conventions. Ireland has extended the scope of control to include a wider range of 
substances in the Criminal Justice (Psychoactive Substances) Act 2010 which applies to 
substances not specifically proscribed under the Misuse of Drugs Acts, but which have 
psychoactive effects by making it an offence to sell, import, export or advertise such 
psychoactive substances. This Act aims to prevent misuse of harmful psychoactive substances.  
 
However, the process by which substances are subjected to legislative control warrants 
ascertainment of abuse potential and harm in order to warrant control. This process is 
underpinned by surveillance and monitoring of trends relating to usage, seizures and health 
effects) in national and international contexts, along with the identification of emerging 
individual chemical substances and groups of substances within drug user groups. Government 
orders control a wide range of substances by virtue of generic definitions, in order to inhibit 
circumvention of legislative controls by creative drug design.  Since 1977, nine Government 
orders have been implemented, with the most recent order in December 2014, following the 
control of several substances by EU Council decisions. Government orders in 2010 and 2011 
controlled substances circulating via headshop retail which included synthetic cannabinoids, 
BZP derivatives and mephedrone. These controls, coupled with the Criminal Justice 
(Psychoactive Substances) Act 2010, assisted in achieving greater control, and the (almost) 
disappearance of head shops in Ireland. Many head shop products became illegal in Ireland on 
23 August 2010 when the new Criminal Justice (Psychoactive Substances) Act 2010 was passed. 
This was followed by the Misuse of Drugs (Amendment) Bill 2015: Second Stage Dail debate in 
Ireland (March) which provides that substances which were controlled before the court 
judgment by means of Government order may be added to the Schedule to the 1977 Act, thereby 
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providing that they will once more be controlled. This Bill aimed to protect the legal framework 
of Ireland by re-controlling substances which were assessed as meriting such control.  
 
Studies on synthetic psychoactive drugs in the Republic of Ireland to date have largely centred 
on the pre and post legislative detection of psychoactive substances (Kavanagh et al., 2010), and 
use of the popular synthetic cathinone drug mephedrone (Van Hout and Brennan, 2011a:b:c; 
2012; Van Hout and Bingham, 2012). One cross border comparative study was undertaken with 
Northern Ireland (McElrath and Van Hout, 2011). In Northern Ireland, drugs are classified under 
the Misuse and Drugs Act, with a series of temporary drug classifications of synthetic drugs 
taking place since 2012 (for example methoxetamine, methyphenidate derivatives, benzofuran 
and indole analogues, and NBOMe hallucinogens). At present the UK is considering legislation on 
legal highs which would make it an offence to produce, supply, offer to supply, possess with 
intent to supply, import or export psychoactive substances; that is, any substance intended for 
human consumption that is capable of producing a psychoactive effect. 
 
Setting of the Research 
Teach na nDaoine is the Family Resource Centre located within Mullaghmatt, Co. Monaghan, 
situated in the Electoral Division (ED) of Monaghan Rural and services Monaghan town and its 
hinterland. It emerged from the Mullaghmatt/Cortolvin Community House Management 
Committee that was set up in 1998 within the local authority housing estates of Mullaghmatt 
and Cortolvin.  The Family Resource Centre has expanded since the facility opened in 2005 and 
the catchment area for supports and services has grown by demand to include the wider 
Monaghan Urban and Monaghan Rural areas.   The vision for the centre is and continues to be 
‘’to work towards meeting the needs of the area through a community development process of 
self-help and with engagement from key stakeholders’’.   
 
Mullaghmatt/Cortolvin is the largest Local Authority housing estate in County Monaghan and is 
located on the western edge of Monaghan town.  The estate was built in the early 1970’s and 
consists of approximately 260 houses.  The estates were built at a time when the conflict was at 
its height in the North of Ireland. The estates became a place of refuge for many people fleeing 
the conflict.  At present, approximately one third of the population of the estate is of Northern 
Irish origin.   The catchment area of Mullaghmatt/Cortolvin has a deprivation index score of -3.3 
compared to the national average of 0.2.  The area has a high unemployment rate (26.9% male 
and 18.1% female), and lone parent households count for 26% of the local population.  The area 
has a higher than average share of low-skilled workers (25.8%) and a significantly lower than 
average share of a professional skilled workforce.  19.6% of adults in the community have 
attained only a primary education, while 24% of the population have attained third level 
education. 
 
With this socio-economic backdrop, ‘‘Herbal’’ use has emerged as a major concern for residents 
and families in the Mullaghmatt area following the deaths of a number of young people as a 
result of their use.  Teach na nDaoine commissioned this research study to obtain clarity on the 
issue and to assist with the formulation of a response. 
12 
 
Chapter Three: Research Methods 
 
Study Aims and Objectives 
The study aimed to provide: 
 A literature review of relevant research and legislation on Synthetic Cannabinoids 
 A baseline measure of licit and illicit drug and alcohol use among a group of ‘‘Herbal’’ users 
i.e. frequency of use; quantity being used, patterns of use; experiences of users; other drugs 
being used in addition to synthetic cannabinoids, history and patterns of drug and alcohol 
use. 
 Documentation of a profile of ‘‘Herbal’’ users including age, gender, marital status, 
educational attainment, educational experiences, employment history, parental drug or 
alcohol use. 
 Documentation of the effects of use of ‘‘Herbal’’ based on users experiences of negative 
effects including physical health, mental health, family conflict, legal issues etc.  
 Exploration of why this cohort uses this particular substance exclusively. 
 Final reporting of research which can be repeated in order to gauge change and that could 
inform the development of an effective monitoring and evaluation framework to enable 
services locally to formulate a response. 
 Provision of recommendations based on research findings that could inform Community, 
Voluntary and Statutory service development. 
 
The objectives of the study were to gain an understanding of individual and collective 
experiences of ‘‘Herbal’’ use; pathways to misuse or dependence; how dependence is reinforced 
and maintained; recommendations for improved targeting of community drug campaigns and 
harm reduction and, finally, recommendations for a road map for future service targeting and 
drug monitoring in the area.  
 
Study Design  
The study design consisted of interviews with ‘dependent’ users (n=6), a community focus group 
(n=10) and interviews with key stakeholders (n=9).  Eight stakeholders and one parent of a user 
were interviewed and represented the perspectives of family, drug and community support, 
mental health, addiction, primary care, council services and law enforcement.  
 
User participants completed the Severity of Dependence Screener (SDS) (Gossop et al., 1995) 
which is a 5-item questionnaire, with scores of over 7 indicating dependence in the past 12 
months.  For the purposes of this study participant with scores of 7 and above were categorised 
in the ‘dependent’ user category, and those under 7 in the ‘recreational user’ category.   
 
Three males (aged 17-38 years) and three females (aged 20-42 years) were interviewed. Five 
dependent (current) users of ‘‘Herbal’’ and one previously dependent (currently abstinent) user 
took part in interview. All user participants scored over 7 in the Severity of Dependence (SDS) 
screener, with average score of 13, and with two scoring the maximum score of 15 (one male, 
one female), two scoring 13 ( two males), one female scoring 9 and one female scoring 12. No 
‘recreational’ users were interviewed.  
 
All user participants were unemployed with three educated to Junior Certificate level, two 
leaving school at primary level, and one educated to Leaving Certificate. All were single, and 
three had children.  
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The in depth interviews and focus groups captured illustrative data pertaining to choices and 
decision making to use ‘‘Herbal’’ products, experience of sporadic and continued use, reinforcers 
for use, perceptions of risk and abuse potential, harm reduction practices, use of other drugs or 
medicines, adverse health and social consequences, favoured route of administration, and 
perspectives on treatment referral, uptake and outcomes.  
 
The interviews and focus groups lasted between 30-90 minutes, and were audio-recorded with 
the participants’ permission.    
 
Photographs of ‘‘Herbal’’ products were also included in order to verify and validate user 
interview data.  
 
Ethics 
The study adhered to ESRC protocols for conducting ethical research. Face to face interviews 
and focus groups were conducted at the participant’s designated service setting in a private 
room.  
 
There were no known risks of participating in the study. Participants were encouraged to 
contact the lead researcher Dr Van Hout via email with any concerns.  In the event of the 
participant becoming uncomfortable or upset, the interview ceased, and the participant was 
referred to their GP or appropriate service provider.  
 
All interviewees and focus group remained anonymous in any subsequent discussions and in the 
final report and publications from the study. All data was retained in confidence.  All interviews 
and focus group were coded for anonymity and stored in a locked filing cabinet.  Audio files were 
destroyed post transcription.  
 
Data Analysis 
The data consisting of 51,159 words was analysed using thematic analysis (Hayes, 2000; Braun 
and Clarke, 2006) which located and identified recurrent explicit themes of experiences of 
‘‘Herbal’’. The data was read several times by both members of the team to familiarise with 
content, with initial patterns identified without preconditions. Each item in the data was coded 
systematically and manually.  Recurrent patterns were sorted into overarching themes, and 
repeatedly checked for consistency, internal and external homogeneity. A written analysis was 
devised with supportive illustrative quotations. Results were repeatedly checked by both 
members of the team to match with the original dataset for verification and consistency.  
 
Validity of the thematic analysis of qualitative data was optimised by the triangulation of 
perspectives on the issue of ‘‘Herbal’’ use from stakeholders, dependent and recovered users, 
parent and community members. 
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Chapter Four: Results 
 
‘‘Herbal’’ Products in Circulation                 
 
A variety of products were described by users and stakeholders in circulation (Blue Joker, Red 
Joker, Clockwork orange, Clockwork Reloaded, Happy Joker, Blueberry, Clock Reloaded and Jammin 
Joker, Juicy Fruits, Cherry Bomb, Black Mamba)  One user described ‘Happy Joker’ as the ‘The best 
of a bad bunch.’  Product commonly contained 5f-AKB48 or 5F-PB-22, or are a combination of 
both.  
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Findings:  Thematic Analysis of Qualitative Data  
 
3.1 Participant Profile 
Three males (aged 17-38 years) and three females (aged 20-42 years) were interviewed. Five 
dependent (current) users of ‘‘Herbal’’ and one previously dependent (currently abstinent) 
user took part in interview.  
 
All user participants scored over 7 in the Severity of Dependence (SDS) screener, with an 
overall average score of 13, and with two scoring the maximum score of 15 (one male, one 
female), two scoring 13 (two males), one female scoring 9 and one female scoring 12. No 
‘recreational’ users were interviewed.  
 
All user participants were unemployed.  Three were educated to Junior Certificate level.  Two 
had left school at primary level.  Only one was educated to Leaving Certificate.  All were single, 
however three had children.  
 
In addition to users, eight stakeholders and one parent of a current user were interviewed which 
represented the perspectives of family, drug and community support, mental health, addiction, 
primary care, council services and law enforcement.  
 
3.2 Emerging Drug Trends in the Community  
This theme describes community and stakeholder perceptions of emergent use of ‘‘Herbal’’ 
products in their community.  
 
Continued use of ‘‘Herbal’’ products appeared to be a legacy of the emergence and 
disappearance of head shops in 2010.  More recently however, awareness of this issue was 
characterised by rising reports of drug use in the community, displacement away from excessive 
alcohol use and related public nuisance, and a reduction in levels of anti-social behaviour.  
‘One of the things we sort of accidentally spotted is that we would have had over the 
years a fairly strong culture of abuse of alcohol in this area. And there would have been 
anti-social behaviour related to that, a lot of people complaining “they’re drinking 
outside me house” at 4 or 5 o clock in the morning, stuff like that. By and large that has 
near enough disappeared in this area. It seems to be the case is that most people, most 
young people, not so young either too, are smoking herbal, in their own houses and 
that’s their escape.’ (Stakeholder Participant) 
 
Stakeholder and community participants described the identification of clustering or ‘pockets’ of 
‘‘Herbal’’ use in certain estates and localised areas, which appeared related to widespread 
availability and social networks of users.  
‘What I find if there does seem to be clusters, it has something to do with availability 
and accessibility as well’. (Stakeholder Participant) 
 
‘Where I am living is a dealing and drop off point in the town, and I just see a constant 
stream of people every single day, and unfortunately after XXX death there was a bit of 
activity to try and mitigate, in terms of the guards being up and walking around, but 
that has really stopped. Its blatant, it’s obvious, it’s totally out in the open, its running 
riot as far as I can gather. (Community Participant) 
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Indicators of this emerging trend also centred on anecdotal community reporting and health and 
primary care service engagement with users in crisis. Other indicators centred on familial use of 
‘‘Herbal’’ products reporting of user possession, littering of herbal product paraphernalia and 
incidences of youth deaths by suicide speculated to be linked to use of synthetic cannabis. 
‘I know there are people smoking it, young people. I’ve had one mother who was 
smoking it along with her children, I think she was taking more than them. Then we’ve 
had one or two suicides as well, so I suppose that’s what I know about it really. I see the 
packets lying around.’ (Stakeholder Participant) 
 
During the last 12 months, mental health, psychiatry and community service uptake had 
increased, perhaps triggered by the first youth suicide in the area, heavy and dependent use of 
synthetic cannabis products and difficulties for users to cease use, and the related negative 
individual, familial and community consequences.  
‘We’ve probably provided service to maybe 20 individuals predominantly male, 
predominantly under the age of 25 all with apparently serious issues around synthetic 
cannabis. A lot more so than normal cannabis and the things that they’re telling us 
seems to indicate that it has much greater potential for addiction and a lot harder for 
them to control their intake, and much more of a propensity to trigger or exacerbate 
mental health issues and it seems to be a serious issue.’ (Stakeholder Participant) 
 
3.3 Profile of ‘‘Herbal’’ Users 
This theme describes community, stakeholder and user perceptions of ‘‘Herbal’’ users.   
 
Stakeholder participants were generally of the view that clustering of use of ‘‘Herbal’’ was 
contained among individuals living in marginalised and deprived areas, and filtering into more 
mainstream communities. One stakeholder observed the clustering of use among the settled 
Traveller4 and Traveller community.  
‘Some of the users are telling me that they’re smoking this stuff just to escape, coz they 
see themselves as unemployable. They don’t see themselves as being able to hold down 
a job, or they don’t see themselves as having any kind of great future. There’s lots of 
other issues that compound this… poverty, lack of opportunity for education, maybe a 
bad experience in school, maybe not having any education or qualifications, so there’s 
many layers, never even mind talking about the addiction issues and how that’s 
affecting their mental health and their stability.’ (Community Participant) 
 
A strong majority of users were described by stakeholders as unemployed, with low level 
education, not engaging in training, with experience of family dysfunction and illicit drug activity 
in their community, and with a history of excessive alcohol use. Many stakeholders cautioned 
around the potential for use across all social strata over time. 
‘The overriding issue is by and large seeing themselves as unemployable. Certainly 95-
96% of the users absolutely have issues in regard to education, dropping out of school 
early, having no formal qualifications, and even from an early age even before they 
would have engaged in certainly this type of drug, would have seen themselves as 
unemployable, a typical response to people who engage in illegal drugs.’ (Stakeholder 
Participant) 
                                                          
4
 The name “Travellers” refers to a nomadic Irish ethnic group. Irish Travellers are a people with a separate 
identity, culture and history, although they are as fully Irish as the majority population. Source Paveepoint. 
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Age profile of users was described by stakeholders as ranging from as young as 13 or 14 years, 
up to early forties. In terms of gender, opinions were mixed, with some stakeholder participants 
describing a gender balance, and others commenting on predominance of male dependent use 
within the 16-25 age category. Emergent outliers in the form of increasing female and older 
users up to age 40 years were observed.  
‘We’ve had the oldest we’ve had is around 42. Most of them have been younger so 
maybe between 18-25 age bracket, mostly males.’ (Stakeholder Participant) 
 
This was corroborated by one user commented who said;  
‘I’d say 70% of XXXX [estate] that, the oldest who smokes it in the park is the wee lads 
mother, and the oldest that smokes it is about 42. It doesn’t go past 42 years of age 
that’s about it.’ (User participant) 
 
Comments centred on the difficulties in estimating prevalence and accurate profile of users 
(with exception of those engaging with services) firstly given widespread accessibility within 
local user communities and via other sourcing routes (dealers, internet, local markets, cross 
border drug tourism) and secondly its covert hidden nature by virtue of consumption in private 
homes.  
‘A determinant in relation to that is probably accessibility and availability, and it’s 
quite readily available. And it wouldn’t be commonly known that they’re using so there 
would be a significant covert element to it as well, so it takes them out of the public 
eye, the public domain and it’s accessible to them’. (Stakeholder Participant) 
‘Working out here XXXX and seeing this new product come on the market opened my 
eyes about a lot of what was going on. I soon realised that the closing of the head shops 
was probably one of the most important things that was done in recent years. But yet 
still didn’t solve the problem. Because we have a border in this country,  eh a couple of 
miles up the road where we are located on the border, its freely available on the 
markets and that, so there’s a whole issue around the law both sides of the border 
here’. (Community Participant) 
 
Users were easily recognisable by their appearance. 
‘The presentation would be very drowsy, weight loss, appearance is very scruffy, quite 
clear to see, recognisable, or someone who’s taking it it’s very easy to see that. Maybe 
dark bags underneath their eyes and their appearance scruffy and their hair greasy,  
that seems to be the profile of how someone on this drug would present themselves. 
‘(Stakeholder participant) 
‘As a local resident its quite obvious and more than anything its quite scary to see the 
physical and mental deterioration of people in the local community. There are some 
people, that I’ve noticed the most is the significant weight loss and I understand if 
you’re putting these chemicals into your body and they are having this detrimental 
physical effect, what is it doing to your brain. How far can these people can push their 
bodies before they die?’ (Community Participant) 
 
3.4 Access and Availability of ‘‘Herbal’’ Products  
This theme illustrates community, stakeholder and user perspectives on availability and use of 
‘‘Herbal’’ products.  
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Stakeholders appeared aware of the diversification of herbal synthetic products, user 
perceptions of safety inferred by legal status, changes in chemical structure and concerns 
around the unknown effects of new market entries, and with a particular concern for associated 
addiction, mental health and related harms (see later thematic sections).  
‘People are actively in the throes of usage before they realise the extent and severity of 
what their dealing with. They don’t know. Unfortunately that’s part of the problem, the 
way it’s being promoted and advertised particularly online, it is to the naked eye or the 
uninformed eye - they would believe it’s very safe and it’s not going to create any 
difficulties.  Even the packaging the way its market would suggest that. And then the 
way it changes, as you know yourself the chemical profile changes, the name changes, 
the packaging and all changes. So they can regenerate all the time, and very 
effectively.’ (Stakeholder participant) 
 
Legal status was observed by stakeholders and community members as confounding efforts to 
control use.  
‘It’s quite visible it’s in everybody’s face, and there seems to be a perception that there’s 
nothing that the criminal justice system can do about it.’ (Stakeholder participant) 
‘I wouldn’t approve of Irish drug law the way it is at the minute, I believe its 
detrimental because it drives drug use underground and my immediate initial reaction 
when I heard about herbal cannabis was, perhaps this was a healthy alternative to 
traditional cannabis, because it has that “herbal” attached to it. Not knowing an awful 
lot about it – that was my initial impression’. (Community Participant) 
 
One user commented that ‘Herbal’’ products should not be legal in Ireland.  
‘It shouldn’t be legal man, it should be illegal. It shouldn’t be allowed it is terrible, its 
killing us all. ‘(User participant) 
 
User awareness around dangers of smoking these products were low, and reliant on personal 
experience (often when too late) and peer user networks, and if accessing services on project 
staff dissemination.  
‘I haven’t really been told what they are, I just experienced it myself so I am just going 
with what I went through’. (User participant) 
‘People started going to the markets and started getting their hands on this stuff, and 
when this stuff did hit, they didn’t realise it was as addictive as what it was, people 
were going and buying and not realising, like myself, not realising how addictive it 
was’. (Community Participant, former user) 
 
Online sourcing of information and bulk purchasing via web retailers, in local market retail and 
door to door delivery was also described. One participant described the use of car ‘blaring loud 
music like the ice-cream man’ as indicating presence of dealers in the estate. Others described 
cross border travel (so called ‘drug tourism’) where users could purchase ‘‘Herbal’’ sold as 
incense in ‘joke shops’.  
‘Sourcing networks are locally obviously, they will tell you that there are dealers 
around XXXX [town] that are easily accessible. XXX market is a market on the border 
area that people were selling it as incense. And the internet, it is easily accessible by all 
account.’ (Stakeholder participant) 
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Some comments centred on its affordable price, ranging between 15 and 20 euro per 1 gram 
bag. User participants described spending between 60 and 200 euro per week on ‘‘Herbal’’ 
products for personal use. Some described receipt of ‘‘Herbal’’ ‘on tick’, with large debts accruing 
over short timeframes, and amounts spent of increasing over time, in response to compulsive 
use. 
‘About 200 euro a week, I get 190 euro a week from here [course] a week. By the time I 
leave here, I have about 4 euro left. That’s how bad it is. I could just smoke it during the 
day, evening, night time, every hours of the morning.’ (User participant) 
‘I could use 3 or 4 bags a day. And they give it out on tick, these dealers like. And so you 
could go to them and say “throw us a bag”, and they’d say “oh that’s alright, dead on 
[name]”. And that could go on until you run up a bill of maybe 3 or 4 hundred euro, it is 
crazy’. (User participant) 
 
Some users described spending their parent’s money as well as their own social benefit. Family 
enabling by virtue of mothers providing basic needs support (food, clothes, home) was equally 
described as exacerbating spending patterns and continued use.  
‘Sometimes the family pay because they want them not to be stealing. What I notice is 
most of the mothers will not pay for the drug, but they will pay for everything else. So 
they pay for the runners and the food and clothes and so on, and try and keep them 
body and soul together. And of course then they have all their dole money for the 
drugs. They are effectively paying for it, I say to them “don’t do that”, but sure if they 
don’t buy them the clothes, they won’t change them or if they don’t buy them food, they 
won’t eat. ‘’ (Stakeholder participant) 
 
Many users described personal neglect in order to buy ‘‘Herbal’’ products.  
‘I don’t even get paid so that’s my mother’s money you know. That’s coming out of their 
pocket too, it’s hard on them too.’  (User participant) 
‘Maybe near 200 euro some weeks, if I could get it then it was got, I got it. I have often 
seen myself starving and buying it’. (User participant) 
 
Alternative income generation and diversification into dealing of ‘‘Herbal’’ products among 
young unemployed was observed by stakeholders and community members and was viewed to 
fuel continued availability, social reinforcement of use and clustering of ‘pockets of user 
networks’ within certain estates.  
‘These guys are in it for money, these young unemployed guys are making 300 euros on 
a Tuesday and about 280 on a Thursday. 600 euros, where they gonna get it? Like 
they’re not gonna get a job like that in XXXX [county] you know.’ (Stakeholder 
participant) 
‘What the people realised was a lot of these so called dealers that I would know of, 
young people I would know, are addicts themselves, they’re selling to keep their own 
habit going. They’re as much a victim to me, they’re all victims’. (Community 
Participant) 
 
3.5 Motives and Reinforcers for Use of ‘‘Herbal’’ Products 
This theme describes the perspectives of users around their motives for experimentation and 
reinforcers for use of ‘‘Herbal’’ products.  
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All users reported smoking of the ‘‘Herbal’’ product as chosen route of administration with no 
reports of insufflation or injecting. Two users reported using a bong, with the remainder rolling 
up with no additives or very little tobacco added. Some users described favouring the rollups 
due to the potency of the bong, others favoured the bong.  
‘Through the bong, it’s the only way I do it. Tobacco? No I smoke it pure and that’s the 
worst way of doing it. When you’re getting that full hit of everything.’ (User 
participant) 
 
Availability appeared first and foremost as driver for introduction and use. 
‘Some of the users that we talked with say and its very simple “it’s the only one that 
they’re selling”. It’s the only one that they’re selling, and it is cheap in the sense’. 
(Stakeholder participant) 
 
Boredom and peer socialisation was mentioned by all user participants as driving initial 
experimentation and continued use, along with its capacity for intoxication.  This was also 
observed by the parent participant. 
‘Boredom, pure boredom, nothing to do. Sitting at home doing nothing all day.  Sure 
it’s no difference like sitting at home smoking, sure you’re doing nothing anyway, just 
lying about’. (User participant) 
‘It’s just boredom, pure and simple, but it’s the younger ones that are seeing all this, the 
older ones is leading by example. They are watching it. Plus they also see the impact 
that it has on the whole house. That won’t matter to them, coz they’ll see they [older 
sibling] got away with it so they’re gonna get away with it’. (Parent participant) 
 
Family dysfunction and socialisation of use between siblings and parents were also viewed by 
stakeholders as further facilitating access, experimentation and social contexts for home use. 
‘There are a number of families who would have heavy users where the functional 
family has collapsed and basically there is none’. (Stakeholder participant) 
 
First-time experiences were described as intensely enjoyable despite experiencing nausea and 
vomiting. All users reported desire to repeat the experience again.  
‘High as a kite, put it that way. Felt brilliant, I thought it was just the best feeling I’ve 
ever had. No feeling better in the world when you have it. No feeling better. You are 
just feel so happy, so “up there”. No feeling like it, when you compare everything and 
everyone.’ (User participant) 
 ‘The first time I says to my friend, “this is a load of shit, I’m getting nothing out of it”. 
And then I stood up coz we were outside sitting on a bench and when I stood up my 
legs wobbled, it just hit me like that!  Then I turned around and said “oh god that’s 
deadly stuff”. That was it then. ‘(User participant) 
 
In addition to intoxication for pleasure, some users reported use of ‘‘Herbal’’ to relieve anxiety 
and low mood.  
‘I would be a worrier. It would make it better, it freezes it, if you know what I mean. 
‘(User participant) 
‘Calm, like when I do have it. Calm relaxing happy, that’s really it. ‘(User participant) 
‘I feel happy, I feel relaxed, I feel calm, I feel the world is on my side. But if I haven’t got 
it I feel the world is against me. I sweat, I can’t eat, I can’t think straight. Yet when I get 
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that smoke everything changes. I’m up real high but if I haven’t got it I’m down as low 
as you can get’. ‘(User participant) 
 
One user described use of herbal as quelling voices in their head. 
‘I imagine there are times when I hear voices in my head telling me to do these things, 
telling me suicidal thoughts, like take an overdose or walk out in front of a lorry, it 
comes. But when I smoke the herbal it seems to keep that voice down a bit, dies the 
voice down a bit, it seems to kill the voice.’ (User participant) 
 
3.6 Patterns and Trajectories of Use  
This theme illustrates user dosage, patterns, and experiences of effect within ‘‘Herbal’’ use 
trajectories.  
 
‘‘Herbal’’ were described as stimulating described ‘warm, happy feelings’, which occurred within 
2-10 seconds, receded over 7-20 minutes depending on user naivety and length of time using the 
product, and were replaced by feelings of agitation and restlessness during the comedown.  
‘Happy feelings. Warm feelings, feel brilliant, but then when that feeling goes away, 
bad. Start feeling angry, pissed off, fighting, calling people names, breaking windows, 
doors, TVs, it’s just not good. ‘(User participant) 
 
Differences in effect were observed within products with some products yielding a dissociative 
effect and others psycho-stimulant.  
‘You get different wee bags, one affects you different to another. Like you could be 
chilled out with that one , you know relaxed. And that one you know your head could 
be racing.’ (User participant) 
‘The ‘Clockwork’ seem to be the one is causing the most damage. The ‘Red Joker’ seems 
to be the milder, I get this from the kids themselves they’re the experts. They switch 
from one to another.’ (Community Participant) 
 
When using fears of having a heart attack, or not walking up when incapacitated were common.  
‘You feel like a heart attack, that you are just gonna die all of a sudden….When my 
father tries to wake me up he cant. I’m in a very very deep sleep like.’ (User 
participant) 
 
Comments centred on how the effect lasted longer in initial timeframes of use, and shortened 
considerably over time. 
‘About 15-20 minutes and that’s it, then you do it all over again, all over again, all over 
again.’ (User participant) 
‘When I first took it, it’d last an hour maybe an hour and a half. See now 10 or 15 
minutes it be gone.’ (User participant) 
 
Users described how the perceived effect changed over time, from pleasure to user realisation of 
tolerance, and experiences of unpleasant withdrawals.  
‘It is not the same buzz now. No definitely not, it’s a shit kinda buzz. It’s the addiction, I 
don’t want it for the buzz, I need it now. Something inside me needs it.  I need to get 
something done with myself.’ (User participant) 
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One participant described using over the course of 3 days, but generally patterns of use centred 
on regular daily smoking. Others only smoked at night (often in response to withdrawals) and 
were able to attend training activities during the day. Three users described using alone, and the 
remainder in small groups, almost always indoors in private homes.  
‘I would do it on my own too, like I would often see me going into the house saying “I 
can’t wait to  get in here” just to be on me own, just to get a bit on me own, just that 
little bit of comfort.’ (User participant) 
 
User participants described using between 1 and 4 grams per day, with volume of use increasing 
quickly following first-time experimenting, and characterised by compulsive re-dose 
consumption despite recognition of loss of control associated harms. Participants did not report 
increasing dose but described increasing frequency of use. Redosing was described as occurring 
every 20 minutes within the ‘‘Herbal’’ smoking episode. 
‘I use 3 gram a day. That’ll do me just one day and like a 1gram bag sure is gone in an 
hours’ time. That’s how bad it is like. I just keep at it. I won’t stop until it is gone. I know 
for a fact it’s killing me like. But I won’t stop it, I just can’t’. (User participant) 
 
Experiences of overdose centred on fear of death, intense chest pain and intoxication, and were 
reported by two participants.  
‘About a week ago, I got 3gram, sat in the room, started doing bongs or whatever. I 
must have done 12 or 13 in a row. And next thing I just sat back and thought “what did 
I just do?” My chest and my heart was beating real fast, I was sweating, everything 
started spinning around me. I tried to stand up, couldn’t, could not stand up. I thought 
“oh here it goes”. Everything just went around me, blurry, and I was going in and out, 
in and out.’ (User participant) 
 
3.7 Displacement from Alcohol and Natural Cannabis  
This theme describes how ‘‘Herbal’’ products appear to have displaced use of alcohol and 
cannabis in dependent users.  
 
All user participants described sole use of ‘‘Herbal’’ at the time of the study, and did not consume 
any other illicit drugs or alcohol. One user had no prior experience of illicit drugs but described 
an addiction to pharmaceutical opioids prior to using synthetic cannabis. Users described 
replacing of one addiction with another. 
‘I don’t bother with the drink. I tell you what there was a time ago, where I would take 
drink and I’d take it quite often. But you see when I got into smoking that herbal, if I 
never seen alcohol again I couldn’t give a damn. You see it takes you from one 
substance to another, like takes you from the drink to the smoke like.’ (User 
participant) 
‘I had a problem with alcohol about 5 years ago. So then I went from one addiction and 
I walked straight into another one. This one here is a lot harder to get off than the 
alcohol.’ (User participant)  
 
All with exception of one user participant described incompatibility of ‘‘Herbal’’ products with 
alcohol. Alcohol consumption was generally low as a result.  
‘I drink about maybe three times a year. But when I drink I black out.  I think it’s the 
herbal as well, blending in the two of them together.. (User participant) 
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Some stakeholders were aware of that alcohol use and risky drinking on the street and in pubs 
has been replaced by smoking of ‘‘Herbal’’ products in private homes. 
 ‘There was something going on in the subcultures we just weren’t aware of. …..we had 
become very aware that this [‘‘Herbal’’]was very prevalent in the community and that 
the good number of users, which was the interesting thing, who were formerly heavy 
users of alcohol, didn’t seem to be using alcohol anymore, or by and large hadn’t been 
using alcohol anymore.’ (Stakeholder participant) 
‘Talking to some of the serious users, they would say that and also people who have 
knowingly abused alcohol, they would be saying that “alcohol isn’t the game now. You 
wouldn’t be bothered with that stuff” they’d be saying and “this is the stuff, this is the 
place to go”. (Stakeholder participant) 
 
Many users described prior experience of use of natural cannabis, and displacement toward 
‘‘Herbal’’ use during periods of lack of availability of cannabis.  
‘To my knowledge, young people started using it, they thought it was like a joint of 
cannabis, they did not realise until much later how addictive it was and how 
dangerous it was and that it affects you physically, mentally’. (Community Participant) 
 
Consistency and quality of the product was a factor in user decision-making, with reports of 
poor quality cannabis stimulating herbal use.  
‘You see it is from one to another. It was hash, it was weed, and then something else 
came along, it was handy you know. As I said it was a quick high, couple drags and you 
are away.  As I said the hash was in flow, and the weed. And you could get weed this 
minute and it be good stuff you get it tomorrow it could be bad. But with herbal it 
seems to be genuine. You’ll get your high any time with herbal. ‘(User participant) 
 
‘‘Herbal’’ albeit recognising that herbal products varied in their psycho-stimulant/dissociative 
effect) also differed in its effect in comparison to natural cannabis.  
‘Nothing compared, weed is nothing compared with it. Strength-wise everything, weed 
is nothing compared. It is worse. When you are stoned [on herbal] you’re not relaxing, 
you’re jumping you are flinching, like those kinda movements [flinching and jerking 
movements], it is not good.’ ‘(User participant) 
‘A lot of them would suggest that they get a cannabis lie feeling, that sort of stoned 
sensation. It seems to go beyond that to some extent I suppose, a lot of them would 
complain that it was quite anxiety evoking, and panic evoking. And there would be a 
lot of sort of motor restlessness, fear, and significant paranoia as well -on occasion that 
would lead to aggression, be it verbal hostility or physical hostility.’ (Stakeholder 
participant) 
 
Further comparisons to natural cannabis centred on the potency of effect incurred from 
‘‘Herbal’’ products, and the patterns of excessive compulsive consumption relating to its short 
lived effect.  
‘The herbal feels a thousand times better, the high. You know the quick high. But then I 
did smoke it for a little while and thinking “how the fuck could a quick high be good”. 
(User participant) 
‘20 quid’s worth of weed would last 3 days. Herbal, a 20 bag of herbal I’d have it gone 
by this time tomorrow.’ (User participant) 
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‘Quickest high of them all would be the herbal. A couple of drags of the herbal and 
cuckoo land you know, but the weed you could sit there all day.’ (User participant)  
‘Talking to some of the users and they’re saying “not interested in alcohol, not 
interested in dope”. Like one fella says “if you smoke major, dope is like going to silk 
cut”. You have to smoke 20 of them before you get any kick, whereas this stuff here 
[herbal] gets you up in the air real high.’ (Stakeholder participant) 
 
3.8 Withdrawal and Dependence  
This theme describes the development of and dependence on ‘‘Herbal’’ products, and the intense 
difficulties experienced by users in trying to wean themselves and cease use.  
 
Many users described thoughts about use of ‘‘Herbal’’ first thing in the morning, with one user 
walking up in the middle of the night to smoke. This thought-process was observed to occur 
quite quickly following initial patterns of use.  
‘First thing in the morning, last thing at night, If I haven’t got it at night time I won’t 
sleep, and nobody else will. I’ll just keep the whole house up’. ‘(User participant) 
‘Coz every 2-3 hours, you’d wake up the same way if you were awake walking around 
like smoking one every couple of hours. It is like in a routine, it has your head in a 
routine like.’ ‘(User participant) 
 
Participants were aware of this fast progression toward regular and dependent use.  
‘They prioritise the herbal stuff above everything else and the patterns of use seem to 
be chronic, literally wake up in the morning – 24/7.’ (Stakeholder participant) 
‘Very bad for the health. If you told me I’d be dead tomorrow morning from that 
herbal, I still couldn’t give it up. That herbal still has an awful hold on me. You might 
have people coming in here to you saying “I took it yesterday, I can do without it today” 
that’s a lie. ‘‘(User participant) 
‘The tolerance levels seems to go very quick, from a couple of pulls to a cigarette to a 
packet to four packets. It is unbelievable nobody realised how addictive this stuff was.’ 
(Community Participant) 
 
Acute physical withdrawal symptoms were reported by users to include chest pains, chest 
pressure, tachycardia and palpitations, lower extremity pain and spasms, nausea, sweating and 
vomiting. 
‘Pains and aches come in if you haven’t got it. Pains in me legs, pains in me chest, in me 
back, pains in me head, pains in me eyes, me eyes go all blurry, it is just that bad. Bad 
pains across me chest, me whole chest, my heart thumping everyday 100 mils an hour. 
Flat out thumping non-stop. Then your hands start to sweat, from me heart or 
whatever, I have to keep me hand on me heart. Like I thought yesterday morning I was 
talking a heart attack, pains across me chest’. ‘(User participant) 
‘Getting up every day, it was like you had to go and get your bag of stuff, like if I hadn’t 
got that bag of stuff I wouldn’t get out of bed. Your humour, like you don’t have it, 
you’re sweating. Like I seen when I wasn’t having it my hands would sweat, my face 
would sweat, it was a nightmare like.’  (User participant) 
 
These symptoms were described as easily addressed by administration of ‘‘Herbal’’.  
‘If I haven’t got it I get the sickness in my stomach, the sweating starts, the weakness 
starts, the sweating starts through the body, the sickness comes then you get the cold 
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shiver through you,  but as soon as you get a smoke of the herbal you are back to 
normal. Back to health again. Which you’re not back to health because your insides 
couldn’t be but you feel level you do’. (User participant) 
 
Concerns were voiced by some stakeholders who were aware of psychological health symptoms 
such as anxiety, agitation, anger, paranoia, self-harm, psychosis, and suicidal thoughts, during 
timeframes of withdrawal. This was corroborated by the users themselves and the parent 
interviewed.  
‘They are frequently reporting paranoia, anxiety, to the point of psychosis and 
delusions, whether there’s an underlying health issue I don’t know. But it seems to have 
triggered those kind of responses in people who wouldn’t have a history. But it is 
difficult because most of them are the typical age of onset for something like 
schizophrenia, so you don’t really know what’s going on. Sleep disturbance, anxiety, 
depression, and suicidal ideation, really common like thoughts of self-harm, voices 
around telling them to harm themselves,’ (Stakeholder participant) 
‘You don’t know what way they’re coming in.  They tried to hide it from me but I knew 
from them coming in and they fly off the handle if they haven’t got it, you know like the 
mood swings, and it is like treading on eggshells half the time.’ (Parent participant) 
‘‘If you don’t have it you feel down, angry. Just bad all the time. Fighting with your 
family over money that they haven’t got. Angry, if I don’t have it, I’m like an antichrist, 
I’ll roar, I’ll shout I’ll kick doors, break windows, Just do anything to get it.’ (User 
participant) 
‘Extremes of agitation as well really restless, and particularly restless when they’re in 
between use, or when endeavouring to stop using, they find it extremely difficult to 
make a concerted effort to actually stop, initially that sort of agitation and that 
restlessness. Very strong desire, compulsion to use the substance again’. (Stakeholder 
participant) 
 
Over time all users described general decrease in function characterised by loss of appetite, 
breathlessness, cardiac conditions requiring medication, skin ablations, tooth decay, lethargy, 
apathy, tremors and insomnia, which were exacerbated when attempting to cut back on use, and 
resulted in general neglect of personal hygiene,. This was supported in some users, stakeholder 
and community participant interviews. Difficulties in eating were most common. 
‘If there was a dinner put out here in front of me now, I’d just look at it and take one 
forkful and say get that away from me, or puke. It is just that serious. Haven’t had a 
dinner in three or four weeks. I can’t eat like me stomach is that bad. I just puke all the 
time. It’s rotten’. ‘(User participant) 
‘They can’t eat something in their stomach, it’s strange I said “what is it like what does 
it feel like?” and they said “we get pain, they can’t eat no appetite!” when they try to 
eat for some reason, it does something terrible to them because they physically can’t 
eat. Like one young person I know of was treated in XXXX for anorexia, even though he 
wasn’t anorexic but that’s what started it. And you can tell nearly by looking at 
someone what stage they’re at. (Community Participant) 
 
Apathy was also a defining characteristic and with associated negative aspects.  
‘My attitude is just ridiculous, I’m lazy, don’t wanna do nothing.’ (User participant) 
‘It makes them very apathetic. The level of use means that they wouldn’t be able to 
work, certainly not with paranoia, sleep disturbance, anxiety all that kind of stuff. They 
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seem to stop eating or they don’t eat properly anyway. They stay in all the time, they 
don’t wanna go out and mix. Close the curtains. And they don’t look after themselves 
very well, they’re not clean most of them, and dishevelled, hoodies, loose baggy pants, 
skinny stomachs, worried mothers, that’s usually what I see’. (Stakeholder participant) 
‘…………….and there’s no more personalities. They’re just entities now, they’re physically 
existing, they’re nothing on the inside, it’s just a body and there’s nothing.’ (Community 
Participant) 
 
Two users reported concern for cognitive impairment, ability to concentrate and short term 
memory loss. Some service stakeholders were aware of this impairment.  
‘Short term memory is significantly impaired and they wouldn’t really have 
recollections of what would happen in the short term, but the longer term memory was 
more intact’. (Stakeholder participant) 
 
All users expressed regret on using ‘‘Herbal’’ products given the unpleasant withdrawals 
experienced. 
‘It’s just a bad dirty drug; I wish I’d never smoked it to be honest with you. Wish I had 
stayed on weed’. (User participant) 
‘Herbal is a curse. I wish I could never see it or smoked it or smelled it or anything. It’s 
a curse on everybody in this town to be honest. Even me own friends like they smoke it 
they sell it too, they say it’s a curse’. ‘(User participant) 
 
3.9 Efforts to Deal with Self-Detoxification  
This theme describes user experiences of self-detoxification.  
 
Some users appeared aware of personal dependence, and described efforts not to use during the 
day by attending training initiatives and avoiding boredom.  
‘Working. Keeping me head occupied. But if I am just sitting in and I start thinking 
about it, that’s it then I’ll just need to go get it. That’s my only problem.’ (User 
participant) 
 
All users described intentions to stop using, and how occurrence of unpleasant physical and 
mental withdrawal symptoms inhibited achieving abstinence. Some stakeholders and parent 
participant were aware of this.  
‘I just can’t. I just have no willpower.’ ‘(User participant) 
‘There seems to be some kind of withdrawal symptoms, where all those symptoms are 
getting worse when they do try to stop. That just kind of locks people into it’. 
(Stakeholder participant) 
‘It is very very severe when you’re coming off that. Herbal is the worst thing.’ (Parent 
participant) 
 
Efforts to cease use and successfully self-detoxify are hampered by widespread availability 
within estates.  
‘You’ll not stop it, not unless something else is done. But for people to stop it 
themselves, I don’t think so coz they haven’t enough willpower. I tell ya there isn’t 
enough willpower around here to help them, there’s not.’ ‘(User participant) 
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For all user participants attempts to self-detoxify in the home periods of between one and four 
days were unsuccessful.  
‘I would love to stop, I’d love to. I stress out too much, I stress out. I have really turned 
around and said “oh yeah I stopped it for a day or 2” but the most I’ve really stopped it 
for is a day, or most of a day, or like before going to bed that day id have had one.’ 
‘(User participant) 
 
Two users commented that if they were incarcerated, they would be able to cease use. The 
recovered (former dependent) participant described a self-detoxification attempt when in 
prison characterised by diarrhoea, insomnia, restlessness, agitation, and sweating, and which 
was concluded within three weeks but with lasting difficulty with sleeplessness.  
‘Diarrhoea, can’t sleep, walking the floors, waking every half hour. Wanting a smoke 
like. Like it took me a good eight weeks to just get my sleep back to normal like and it 
took me I’d say a good four weeks when I was in the prison, for me to be “me”, if you get 
me.’ ‘(User participant) 
 
One user described using alcohol to assist withdrawals.  
‘I’d use a good bit of it [alcohol] to try not smoke anything. I try drink to get off smoke 
but then I can’t do that no more either like.’  ‘(User participant) 
 
One user described attempts to return to use of cannabis, which was viewed as a lesser of two 
evils, and more manageable.  
‘I am trying to get back on the weed, you know. I don’t want this shite because, with the 
weed, I could smoke a joint of weed now and I wouldn’t want another one for two 
hours, Weed, you can eat properly, you can sleep properly. Herbal not at all. I know one 
of the dealers, he’s trying to get as much weed in as possible because he doesn’t want 
the boys on herbal.’ (User participant) 
 
Two user participants described suicidal feelings around efforts to disentangle from addiction.  
‘I just hate it, dirty curse. So hard to get off it, so hard to do anything. I dunno what I 
am gonna do. I don’t know how I’m gonna get off it, or how I’m gonna do it. The only 
way I can think of getting off ……it is just one way. There’s only one way of getting off 
herbal and that’s taking yourself out of this life’. (User participant) 
‘I don’t wanna hurt meself, but it’s gonna come that far. It’s gonna happen. I don’t 
wanna die, I’m only 25 I’m too young to die. But the way it’s all coming in around me, it 
just takes a lot out of you. Some mornings I just wake up feeling so down, you just 
wouldn’t care if you walked out in front of a lorry, it’d make you feel good. ‘(User 
participant) 
 
The fear of stopping was grounded peer experiences of youth psychotic behaviours, suicidal 
ideation and suicide attempts when in withdrawal.  
‘I feel some of the young people I work with there’s one or two in particular I’m trying 
to work with, now it’s their decision it has to be them to make the decision to stop, but 
there seems to be a fear of stopping. There’s one or two people around here that people 
claim have gone mad when they tried to stop.’ (Stakeholder participant) 
 
Experiences of bereavement of peer users who had committed suicide were described by four 
users, and were observed to contribute to fear around coming off the drug.  
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‘I lost a brother last year over herbal, lost a best friend over herbal as well. He hung 
himself, he was 22. Then me brother he was 29, he died in a fit last year. It is all herbal. 
Herbal is the biggest part of it. Like I know it’s the herbal that killed them, but I can’t 
stop.’ (User participant) 
‘I had a cousin that died 3 months ago and I think it boiled down to herbal, but I can’t 
swear that, but the herbal could be a lot got to do with it.’ (User participant) 
 
3.10 Help Seeking and Enhanced Service Pathways  
This theme illustrates the user, parent, stakeholder and community perspectives on how to deal 
with the issue of ‘‘Herbal’’ use in the area in a proactive and concerted manner.  
 
Existing legislation around psychoactive properties of ‘‘Herbal’’ were observed to create law 
enforcement difficulties.  
‘As a community response unit, the Gardaí are supposed to be there to maintain order, 
regardless of whether it’s legal or illegal.’ (Community Participant) 
‘The problem is bigger than here, this is something that needs statutory intervention 
because we can sit here, we can do this, we can do that, we need a higher power, I 
suppose political representatives that can go there in the Dail and place some kind of 
bill or some kind of legislation that will either come up with the idea of allowing 
certain drugs to be legal, that will allow for regulations to happen so  they can be used 
freely and socially acceptable like alcohol, or else a ban on these legal highs that we 
have there. (Community Participant) 
 
Awareness around new market entries and dynamics in drug markets appeared to highlight the 
need for enhanced surveillance and monitoring of trends.  
‘We’d be very aware that when this stuff goes off the market as it will do some time, it 
will be replaced with something else. So the need for a community to have that skill in 
dealing with addictions is something that we need to build on I suppose.’ (Stakeholder 
participant) 
 
Other comments centred on continued and developed CCTV monitoring for certain areas where 
clustered use of ‘‘Herbal’’ use is evident. 
‘Look one of the things that may come out of this piece of work hopefully is that we 
have 12 cameras in this area. That’s like 12 guards on duty, so we’re not maximising 
this by any stretch of the imagination.’ (Stakeholder participant) 
 
Services and community members appeared aware of current demands for crisis help seeking 
behaviours and concerns for longer term impacts on mental health services and associated 
impacts on the community.  
‘We will have people, young people, with serious psychiatric difficulties living in our 
community on a long term basis over the next number of years. There is a number of 
very chronic users and unfortunately there is a street bet that they won’t be living by 
Christmas.’ (Stakeholder participant) 
‘I think from the community’s end I think the community is exhausted. We have had 
two deaths of two young people in a very short period of time, the first male suicide in 
30 years, shock, horror, stunned. Then four months later another one….And the older 
community were saying “why won’t these young ones just listen?” And they don’t want 
to examine the issue of addiction.’ (Stakeholder participant) 
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‘There are people unemployed, they can’t get out of bed in the morning, because this 
stuff wakes them up every two hours during the night, to collect their dole money. They 
should be on sick benefit, because they are sick, very sick. Very ill, it is an illness, a very 
serious illness. A lot of them haven’t got medical cards. Even to access help, their whole 
way of life just gone, they live to get money to buy this stuff because it gets such a grip 
on them. Also, the long-term health effects are horrendous. We’ll never know what the 
long term effects are going to be but the community really feels they’ve been let down, 
by all the government agencies, nobody is doing anything. (Community Participant) 
 
Frustrations were voiced with regard to the situation and lack of formulated service response.  
‘I would have to say that we experience a lot of…., people aren’t pleased with what we 
have to offer.’ (Stakeholder participant) 
‘There’s a lot of frustration and they’re frustrated with us and with all the services. I 
think because we can’t necessarily stop someone or break this compulsive pattern of 
use, that’s been a real source of frustration.’ (Stakeholder participant) 
‘And in a tight knit community that’s much worse, and in a tight knit community that 
feels like they’ve been dumped upon by services for years and years, there’s no faith in 
the services’. (Community Participant) 
 
Community frustrations around what to do and stigma relating to addiction, and fears around 
negative labelling of estates, labelling as drug addicts and children’s socialisation into use were 
voiced. Community empowerment and advocacy warrants investment. 
‘Since this has become public, I’m getting a sense from some of the younger people, that 
I think they’re trying to hide the fact that they’re using this a lot more now, I think 
there was a sense maybe before XXXX died, before there was  public anger about the 
issue, I think the younger people would have been inclined to admit to it more because 
it was legal, because there wasn’t such a stigma attached to it all, and I think there has 
been a stigma developing, however I don’t think it’s changed the levels of usage. I think 
the young people are trying to tell us that they’re not using, or they’re off it, or 
whatever it might be, when the reality doesn’t seem to back that up. (Community 
Participant) 
‘There’s also child protection issues, very young children and their parents are taking 
this stuff, they’re exposed to this stuff, and they’re walking around picking it up off the 
street. Sometimes parents and children are fighting over it. Fighting over who needs it 
the most.  [Response from the focus group participant] Like one of the children at the 
centre one time, the guards said to report all these things and the child said “how do 
you expect me to report my mommy and daddy.” (Community Participants) 
 
Community empowerment and advocacy warrants investment. 
‘I would have said that the community needs to be educated because we’re kind of 
afraid to approach what we don’t understand, so that’s one of the issues around here. 
So I think education is probably the best way for the local community to address this 
issue further, because people are so ignorant and they won’t tolerate these druggies 
because they don’t really understand them. (Community Participant) 
 
Efforts to access services in some instances were deemed complicated by lack of recognition and 
stigma related to drug addiction, and with community health supports at times requiring 
specialist training in addictions and presence of drug counsellors.   
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‘It’s the social acceptance, the taboo of using drugs, there’s a significant taboo and you 
find that with parents the whole thing is very much stigmatised,’ (Stakeholder 
participant) 
 
Families were deemed to also try to deal with the issue internally, and highlighting the need for 
enhanced community outreach, low threshold access to support and treatment, and family 
education. For young people identified with psychosis, supports were in place in the form of 
‘COPE’ program which is Care and Overcoming Psychosis Early. 
….what you find is the family try and solve the problem themselves. Sometimes they 
don’t know. And they don’t know specifically what the person is using because there is 
a covert element to it as well. But you will often find in relation to it they will try to 
solve the problem, they wouldn’t necessarily seek help from services, they wouldn’t seek 
help from people outside the family, until it sort of reached crisis situation,…. We need 
to develop family focused workable prevention strategies. They need to be working 
with the family, sort of family skills training, even parenting and so on.’ (Stakeholder 
participant) 
‘What I would argue would be low threshold access. And probably that is best achieved 
through an outreach approach, where there’s individual’s actually in the community 
you know. And they potentially would advocate for the person and they would be the 
link between maybe primary and secondary services, and so on. I think that’s vitally 
important.’ (Stakeholder participant) 
‘Ideally you should outreach to those people, that aren’t going to engage. Addictions, it 
is well-known, that there should be outreach.’  (Stakeholder participant) 
 
An integrated all inclusive approach characterised by community empowerment and inter-
agency approaches were viewed as important steps forward. Community advocacy warrants 
investment. 
‘The community is the one at the forefront, they’re the initial contact so they’re vital. 
……formulation of agreed protocols.  So if a situation arises or they come to the initial 
point of contact, that these individuals themselves know what we do, who we can 
source, how we source them and how we go about it. And that should be available to 
everybody and I suppose that would go again with education and so on, and training 
and so on. I mention as well about regional task force involvement. I think it is 
important to them as well, take your policymakers and people that are involved to that 
level, that need to be privy to what’s going on locally, and they need to endeavour to 
help us and well as local responses you know.’ 
 
A two-pronged approach incorporating prevention and early identification and management 
was viewed by stakeholders as important and warranting further development in harm 
reduction tactics providing information around product legality, risks and harms, overdose 
prevention tactics, counselling for those wishing to stop and what to do in the case of agitated 
withdrawal for all affected parties. Harm reduction efforts had taken place in the form of 
leafleting in identified areas (see appendices).  
‘Drug education and harm reduction is in this area non-existent, except for the pieces 
we do. To get to this particular substance and to get people information about this 
substance, you’ve seen the leaflet – we dropped that out to every house, we give it to 
young people, we talked to a good number of the users.’ (Stakeholder participant) 
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Stakeholder comments centred on the need for enhanced primary care awareness of the issue 
when presenting, and expedited pathways toward medical treatment and counselling.  
‘General Practice is a vital cog in all of this you know, I think they’re intrinsic to 
anything really because they’re the first point of contact often.’  (Stakeholder 
participant) 
 
Shared care systems were viewed as offering success. 
My understanding in relation to the response locally was from a mental health 
perspective, was that you were talking shared care with the local general practitioner 
and I know there was, if required a pharmacological intervention where the person 
was put on medication for a short period of time, the person was put on 
chlordiazepoxide [Librium] to negate withdrawal symptoms, and the other was 
olanzapine probably to negate any psychotic symptoms, to help reduce agitation, like I 
know olanzapine and a drug called Risperdal, that’s an anti-psychotic, but wasn’t 
given specifically for psychosis, it was given because there’s a tendency for this 
impulsivity as well, poor decision making and just acting out and aggression and so on. 
‘(Stakeholder participant) 
‘From a clinical perspective, clinical care plans, group work psychosocial support and 
access to residential treatment as well as and if required.’ (Stakeholder participant) 
 
Issues relating to suicide attempts and difficulties in mental health certification or arrest under 
the Mental Health Act were viewed by parents and some stakeholders as compounding 
difficulties in securing treatment for the young person in question. Other difficulties centred on 
the uptake of users in crisis into the mental health services under the referral of dual diagnosis, 
when likely psychotic symptoms are deemed secondary to drug misuse, and not due to an 
underlying mental health disorder.   
‘General practitioners ring in and try to refer somebody in that is probably not a dual 
diagnosis, but is in withdrawal or is having problems that way, so we would offer 
advice, and advice on medications and what to give when in the withdrawal state, but 
we don’t necessarily see people obviously if they haven’t got a mental health problem.’ 
(Stakeholder participant) 
‘There’s a dis-ownership of addiction and drug related issues by mental health services, 
so that’s challenging.’ (Stakeholder participant) 
 
Current dependent user participants described intentions to seek help and requests for help 
despite fears around detoxification. Community members were aware of the need for drug 
counselling support. 
‘Long term we need counselling, even if you are off this stuff, it doesn’t, even with 
support, it’s not gonna go away overnight’. (Community Participant) 
‘‘They desperately, desperately need help. No more than anybody else with a mental 
illness, a physical illness, desperate. And there’s nowhere to go. Parents are trying to 
get them somewhere, there’s nowhere to take them absolutely nowhere’. (Community 
Participant) 
 
Enhanced support with trained drug counsellors, visibility of detoxification service pathways 
and how detoxification practices work are deemed necessary.  
‘I was looking hoping to get in somewhere to get help with this one because I can’t get 
off this one at all.’ (User participant) 
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‘ I know it’s up to each individual to actually make the step and come off it themselves 
but if there was more help available to do that, more education, to explain more of 
what will happen when you come off it, and how long the detox will take, all that has to 
be explained.’ (Parent participant) 
 
Users and community members expressed desire for residential detoxification provision in the 
area and with sufficient length of step down care.  
‘They need somewhere they can detox safely with a nurse or doctor or medical 
professional or somebody. And then after that week when they’re detoxed then they 
can come out, then they can start going to narcotics rehabilitation.  They need to be 
somewhere for a week where they don’t have kids going “Take a bag, take a bag”, you 
know. “One bag won’t kill ya” and they having 6 or 7 bags in their system as it is. 
(Community Participant) 
‘What’s more important is that it’s an immediate response.  An emergency response. Its 
on-going support. First to recognise it’s an emergency – we need this help, we’re crying 
out for it. We need the funding, we need the will to do this, we want them admit there is 
a crisis, there is a crisis in this area, need the funding, need the medical expertise, we 
don’t know what like if we try to detox young people or children, we could be doing 
them serious harm we could be doing it wrong, we don’t know. There’s a lot of people 
talk about community detox “it’s too dangerous for that. It’s too strong stuff” all we 
can do is the best, experts medically qualified people first of all to look after their 
physical and mental health and hope it’ll not kill them getting off this stuff.. 
(Community Participant) 
 
Some stakeholders expressed the need for youth specific and expedited routes to treatment 
when the young person indicates desire to stop. 
‘To get away from it I need to be put into a clinic. Away completely away’. (User 
participant) 
‘I’d have to go to a dry out centre. I’d have to get out of the estate like. There’s no point 
going for a day or two, I’m not that strong, I’d have to go away for a while like. And be 
cleared and then you could face society then.’ (User participant) 
‘And there needs to be a faster response. Ideally you should have dedicated 
stabilisation units for this kind of thing, particularly geared towards younger people. 
But in the meantime like where else but psychiatry. ‘(Stakeholder participant) 
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Chapter Five: Discussion  
 
This study examined user, service stakeholder, community and family experiences of  ‘‘Herbal’’ 
use on their communities. Stakeholders and the community voiced concern about the ‘moving 
target’ of designer herbal synthetic products, widespread availability exascerbated by flaws in 
existing legislative controls, user perceptions of safety inferred by its sale as incense, normalised 
peer use and legal status. The research whilst localized to certain communities in the North East 
of Ireland, underscore the increasing concerns around the dynamic nature of the synthetic drug 
market, and diverse range of serious health effects in the case of ‘‘Herbal’’ products.  
 
Clustering of use within certain estates and localities appeared driven by peer and familial 
socialisation into use of ‘‘Herbal’’, a lack of clarity regarding the legal status of products, ready 
availability (via local dealers, markets, cross border drug tourism, door to door delivery and the 
internet), affordable price, and factors relating to youth boredom, unemployment and low 
educational attainment. Key indicators were increased service demands, littering of product 
paraphernalia, user displacement away from excessive public drinking and toward hidden use of 
‘‘Herbal’’ in private homes, and the resultant reduced anti-social behaviour relating to alcohol. 
 
A variety of products were in circulation (Blue Joker, Red Joker, Clockwork orange, Clockwork 
Reloaded, Happy Joker, Blueberry, Clock Reloaded and Jammin Joker, Juicy Fruits, Cherry Bomb, 
Black Mamba)  Smoking was the only route of administration (bong, rollups) and with little 
additives such as tobacco. This is reciprocated in the literature (Deluca et al., 2009). There were 
no reports of recent powdered variants (Kikura-Hanajiri et al., 2011). Market driven pricing was 
evident with 1 gram bags selling for between 15 and 20 euro. However, despite affordability, 
spending patterns increased severely over time and with related negative repercussions for 
personal welfare and family relationships.  Diversification into dealing of ‘‘Herbal’’ products 
among young unemployed was observed to fuel continued availability, social reinforcement of 
use and clustering of user networks within certain estates.  
 
Users when progressed toward dependent use were easily recognisable by their neglected 
appearance.  Age profile of users ranged from as young as 13 or 14 years, up to early forties, and 
with some inferences toward majority young male use of this drug in the 16-25 year category. 
This is supported by other ‘‘Herbal’’ studies presenting data on users as young adults and 
adolescents, with average user age of 23 years, with males more than twice as likely to use 
‘‘Herbal’’ (Castellanos et al., 2011; Forrester et al., 2011; Hu et al., 2011; Vandrey et al., 2012; 
Hoyte et al., 2012; Barratt et al., 2013; Papanti et al., 2013), and significantly associated with 
male gender, not attending school and use of cigarettes, excessive alcohol use, marijuana use 
(daily and weekly) and other drug abuse (Caviness et al., 2014). Clinical case report literature 
also indicates greater presentations by male adolescents, and to a lesser extent, young females 
(Zimmermann et al., 2009; Bryner, 2010; Mir et al., 2011; Young et al., 2011; Schneir et al., 
2012).  
 
Awareness of harms associated with use in general was low, with regard to the contents, toxicity 
and dangers in consuming ‘‘Herbal’’. Reasons for experimentation and continued use in this 
small study were described by users as centring on boredom and widespread availability via a 
variety of socialisation and sourcing mechanisms, potency of effect, as well as perceptions 
relating to legality inferring safety (see also Wilkins et al., 2007). Internet retail, marketing 
comparisons to cannabis, availability, affordability, safety and legal perceptions, attractive 
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packaging and price are reported as influencing decision-making (Schifiano et al., 2009; 
Vardakou et al., 2010; Fattore and Fratta, 2011; Every-Palmer 2011; Vandrey et al., 2012; 
Barratt et al., 2013; Spaderna et al., 2013; Winstock and Barratt, 2013; Meshack et al., 2013; 
Gunderson et al., 2014). Marketing as ‘harmless incense’ has contributed the user perception of 
safety (EMCDDA, 2009, Seely et al., 2012a, Seely et al., 2011; Fattore and Fratta, 2011). Studies 
have shown that users initially believe the product is safe and natural (Every-Palmer, 2011). 
Similar findings emerged in this research. 
 
In contrast to literature describing the association between concurrent and sequential use of 
illicit drugs and alcohol with ‘‘Herbal’’ (Barratt et al., 2013; Winstock and Barratt 2013; Schifano 
et al. 2010; Castellanos et al., 2011; Hu et al., 2011; Vandrey et al., 2012; Vandrey et al., 2012; 
Winstock and Barratt, 2013; Caviness et al., 2014), none of the users in this research used other 
drugs and very little alcohol whilst using ‘‘Herbal’’.  All with one exception had prior experience 
of alcohol and illicit drugs. Also, all with exception of one user participant described 
incompatibility of ‘‘Herbal’’ products with alcohol. Alcohol consumption was generally low as a 
result.  
 
Users reported prior experience of cannabis, and described market displacement toward 
‘‘Herbal’’ use during periods of lack of availability of cannabis, and due to affordable pricing of 
“Herbal”. Factors influencing users to move away from use of cannabis toward herbal also 
centred on the potency and consistency of synthetic herbal products. In addition, ‘‘Herbal’’ 
products are marketed as natural cannabis substitutes (Sobolevsky et al. 2010; Sopris 2008; 
Tung et al. 2012; Gunderson et al. 2012).  Acute effects relating to spectrum and intensity differ 
between herbal and natural cannabis (Brents et al., 2012; Brents et al., 2011; Chimalakonda et 
al., 2012; Spaderna et al., 2013). Users in this study commented on the short lived effect, 
compulsion to use and re-dose with herbal products in comparison to the longer lasting effects 
of cannabis.  In contrast to studies which indicate herbal synthetic users prefer the effects of 
natural cannabis to the synthetic variety (Winstock and Barratt, 2013; Arfken et al., 2014), users 
in this study exclusively chose “Herbal” products over cannabis.   
 
First-time experiences were reported as intensely pleasurable characterised by euphoria, 
calmness, relaxation and feeling of well-being despite nausea, and with a desire to repeat. The 
effect was short lived lasting up to 15 minutes, with re-dosing common, with between 1 and 3 
gram consumed in one smoking session.  Once all contents were smoked, happy and calm 
feelings receded and were replaced by feelings of agitation and restlessness.  Whilst the reported 
effects were similar to other studies (Schnier et al., 2011; Fattore and Fratta, 2011; Kjellgren et 
al., 2013), solitary use was favoured and with majority use occurring in private homes.  This 
contributed to difficulties in services estimating prevalence of use.  
 
Differences in effect were observed by participants  within products, with some products 
yielding a dissociative effect and others psycho-stimulant. Subjective and physiologic effects 
reportedly vary depending on content (Schifano et al., 2006: 2009; Benji, 2010; Vardakou et al., 
2010).  Nausea and emesis were described by these users in contrast to the appetite stimulation 
commonly reported by cannabis users (Canning et al., 2010; Hermanns-Clausen et al., 2013).  In 
addition to its pleasurable effect, some users also reported using for relief from hearing internal 
voices, and for relief of anxiety and low mood.  Frequency of use increased over time to become 
regular daily smoking.  
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The study is supported by earlier netnography work presenting user reactions during acute 
intoxication, hangover the day after intoxication, and dependency and withdrawal from long 
term use (Kjellgren et al., 2013; Spaderna et al., 2013; Soussan and Kjellgren, 2014). Acute 
physical withdrawal symptoms included internal restless, urge to consume more drugs, chest 
pains and pressure, tachycardia and palpitations, lower extremity pain and spasms, nausea, 
sweating and emesis. These symptoms were described by users of this study as easily addressed 
by further consumption of ‘‘Herbal’’.  There appeared to be a blurring between comedown and 
withdrawal in user experiences over time., contributing to a compulsive pattern of use and 
associated negative consequences. 
 
Acute toxicity was reported, similar to available literature (Lapoint et al., 2011; Simmons et al., 
2011; Helander et al., 2013), and characterised by fear of death, dissociation, intense chest pain 
and intoxication, which were reported by two participants. Loss of consciousness and confused 
states, panic attacks, suicidal ideation and suicide attempts were described in this study and 
reciprocated in other studies (Gay 2010; Seely et al., 2011; Simmons et al., 2011; Hurst et al. 
2011; Van der Veer and Fiday, 2011; Shanks et al. 2012).  Most concerning were the reporting of 
user suicidal ideation and feelings of self-harm, and sibling and peer suicide during times of 
withdrawal or restricted us, and user and community fears around psychiatric effects of this 
new synthetic drug. Emergency hospital presentations have described case presentations with 
severe agitation, panic attacks, tachycardia, nausea, paranoid ideation, and hallucinations 
(Piggee, 2009; Banerji et al., 2010; Bebarta et al., 2010; Vearrier and Osterhoudt, 2010). It is 
unclear whether these symptoms emerge immediately, minutes or hours post consumption, and 
may commence immediately, minutes or hours post use (Bebarta et al. 2012; Sobolevsky et al. 
2010).  
 
Users in this study reported psychiatric effects underpinned by intoxication and withdrawal and 
exacerbated in periods of attempts to restrict use. Agitated delirium lasting for several days has 
been reported in other studies (Berry-Caban et al. 2013). We know that psychotic reactions to 
‘‘Herbal’’ such as auditory and visual hallucinations, perceptual alterations, illusions, paranoia, 
agitation, aggression, catatonia, depersonalization, and dissociation (Castellanos et al., 2011; 
Every-Palmer, 2010:2011; Schneir et al., 2011; Spaderna et al., 2013), are often the common 
reason for the seeking of medical assistance (Forrester et al., 2011), and with episodes 
prolonged and persistent, and sometimes never remitting (Hurst et al. 2011; Van der Veer and 
Fiday 2011; Tung et al., 2012; Berry-Caban et al. 2013).  This was observed to complicate 
admissions to mental health versus detoxification services. Debates continue around whether 
use of herbal synthetic cannabinoids precipitates psychosis in individuals with and without a 
history of psychotic disorders (Every-Palmer 2010:2011; Müller et al., 2010; Hurst et al. 2011; 
Pierre, 2011).  
 
Withdrawal reactions when actively detoxifying are reported to mostly resolve within a week 
(Zimmermann et al. 2009; Rominger et al. 2013).  In contrast, the recovered user in this research 
who had achieved successful self-detoxification (whilst incarcerated) reported up to three 
weeks for acute withdrawal symptoms to subside, and longer thereafter to feel fully normal. 
Psychotic symptoms, along with awareness of peer suicides, and the development of suicidal 
ideation and self-harm reported in this research contribute to a fear of detoxification, and 
stimulated help seeking from Mental Health Services when in crisis. Unsuccessful attempts at 
self-detoxification were reported by others and were generally between one and four days, with 
some users using alcohol, cannabis to manage withdrawals, and attempting to restrict use by 
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attending training activity during the day. Detoxification efforts were further hampered by 
widespread social cues for use and availability, alongside fear of psychosis and self-harm.  
 
Whilst research suggests the presence of three distinct groups of users (for example marijuana 
users, casual users seeking to avoid detection, and naïve drug experimenters), this study 
highlights the addictive nature of ‘‘Herbal’’ products, where many users were described as 
quickly adopting dependent use patterns. No recreational users were available for participation 
in the research. Dependent use was characterised by intense thought processes around seeking, 
using and sourcing the drug, and evidence by the high SDS scores of participants. Many users 
described thoughts about use of ‘‘Herbal’’ first thing in the morning, with one user walking up in 
the middle of the night to smoke.  
 
Consequences of long term use centred on general decrease in function characterised by loss of 
appetite, breathlessness, cardiac conditions, skin ablations, tooth decay, lethargy, apathy, 
tremors and insomnia, all exacerbated when attempting to cut back on use, and general neglect 
of personal hygiene,. Concern for cognitive impairment, ability to concentrate and short term 
memory loss were voiced, (similar to extant literature, Musshoff et al. 2013), and often lasting 
longer than the intoxication period (Kjellgren and Soussan 2014). One user reported cardiac 
abnormality as result of use, with studies suggesting that ‘‘Herbal’’ may precipitate myocardial 
infarction and even death (Mir et al. 2011; St. James 2010).  
 
Continued monitoring and surveillance of drug trends and drug activity is warranted based on 
the findings of this research. Community efforts to act as medium for family support and 
education, harm reduction and detoxification care pathway dissemination offer additional 
approaches to early identification of trends in use, misuse and dependence, and the support of 
individuals requiring help. Further development of appropriate clinical responses is equally 
needed, alongside the expedited inter-agency pathways for drug counselling, crisis support and 
detoxification intervention for users and their families. 
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Chapter Six:  Conclusion & Summary of Key Findings 
 
Use of SCBs in herbal smoking mixtures is a public health concern given reporting of acute CNS 
and cardiovascular toxicity with severe cardiovascular, gastrointestinal and psychiatric sequelae 
(Gunderson et al. 2011; Brents & Prather, 2014). Despite efforts to regulate, use of SCBs among 
adolescents and young adults has increased in popularity over time. The ever changing 
composition of herbal smoking mixtures and uneven consistency in the diverse range of 
products contributes to experiences of undesirable effects and the risk of accidental overdose 
(Uchiyama et al. 2010a,b; Seely et al. 2012).  Concerns centre on dearth of research on 
pharmacology, toxicology and health consequences in humans, and appropriate medical 
approaches for treatment of acute intoxication and management of detoxification (Fattore & 
Fratta, 2011; Rodgman et al., 2014).  
 
Key findings are as follows; 
 
‘Herbal’ as an Emerging Trend 
 Awareness of the current issue was characterized by rising reports of drug use within 
the community, displacement away from alcohol use and a reduction in anti-social 
behaviour. 
 Difficulties estimating prevalence and profiles of users stemmed from widespread 
availability within local communities and other sourcing routes i.e. internet, cross-
border drug tourism, and due to the hidden nature of use in private homes.  
 Clustering or pockets of “Herbal” use appeared related to availability and social 
networks of users, contained among individuals living in more marginalized and 
deprived areas, and filtering into more mainstream communities. 
 
Profile of user 
 All user participants scored over 7 in the Severity of Dependence (SDS) indicating all 
users interviewed were dependent on “Herbal”.   
 All user participants were unemployed.  Three were educated to Junior cert level, two 
were educated to Primary level, and one educated to Leaving cert level. 
 All user participants were single.  Three had children. 
 
Legal status and availability of ‘Herbal’ 
 A lack of clarity regarding legal status was observed by stakeholders and community 
members as confounding efforts to control use.  Existing legislation around psychoactive 
properties in SCB’s were observed to create significant law enforcement difficulties.   
 User participants described cross border travel, so called drug tourism, where they could 
easily purchase “Herbal” products sold as incense in joke shops. 
 User comments centers on the initial affordable price, between 15 to 20 Euro per 1 gram 
bag.  User participants described spending between 60 and 200 per week on “Herbal” 
products for personal use, with amounts spent increasing over time in response to 
compulsive use. 
 
Awareness of harm and Consumption of ‘Herbal’  
 User awareness around the dangers of smoking “Herbal” products was low, and relied on 
personal experience (often too late), peer user networks, and project staff dissemination. 
 All users described exclusive use of “Herbal” and did not consume any other illicit drugs 
or alcohol.  Users reported an incompatability of “Herbal” with alcohol.  Alcohol 
consumption was generally low as a result. 
 
Trajectories of use, dependence and withdrawal 
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 Users described how the perceived effect changes over time, from pleasure to user 
realization of tolerance, and experiences of unpleasant withdrawals.  Users became 
aware of the fast progression toward regular and dependent use when it was too late.   
 Acute physical withdrawal symptoms were reported to include chest pains, chest 
pressure, tachycardia and palpitations, lower extremity pain and spasms, nausea, 
sweating and vomiting.   
 Stakeholder reported psychological symptoms such as anxiety, agitation, anger, 
paranoia, self-harm, psychosis, and suicidal thoughts during withdrawal periods.  These 
were corroborated by users and parents interviewed.  
 
Chronic outcomes  
 Over time all users described a decrease in functioning characterised by a loss of 
appetite, breathlessness, cardiac conditions requiring medication, skin ablations, tooth 
decay, lethargy, apathy, tremors and insomnia, which were exacerbated when 
attempting to cut back on use, and resulted in general neglect of personal hygiene,. 
Difficulties in eating were most common. 
 Users also expressed concern about cognitive impairment, ability to concentrate and 
short term memory loss.  Stakeholders were aware of this impairment. 
 
Intentions to Stop and Help-seeking Attempts 
 All user participants described intentions to stop using, and how unpleasant physical and 
mental withdrawal symptoms inhibited achieving abstinence.  The fear of stopping use 
was also grounded in youth psychotic behaviours, suicidal ideation and suicide attempts 
when in withdrawal. 
 Efforts to cease use and successfully self-detoxify are hampered by widespread 
availability.  Users commented that if they were incarcerated, they would be able to stop 
using.  Users also reported using other substances i.e. alcohol and cannabis to assist with 
withdrawals. 
 
Stakeholder and Community Experiences and Observations 
 Services and community members appeared aware of current demands for crisis help-
seeking behaviours and expressed concern about long term impacts on services and 
associated impacts on the community. 
 During the last 12 months, mental health, psychiatry and community service uptake by 
SCB users in crisis has reportedly increased.   
 Frustrations were expressed regarding the perceived “dis-ownership of addiction and 
drug related issues” and the lack of a formulated health service response.   
 Concerns were expressed regarding the uptake of users in crisis into mental health 
services under the referral of a dual diagnosis, because psychotic symptoms are deemed 
secondary to drug misuse and not due to an underlying mental health disorder, 
compounding difficulties in securing treatment for the young person.  
 
Responses and a Way forward 
 An integrated, all-inclusive approach, characterized by community empowerment and 
inter-agency approaches were viewed as important steps forward.  Stakeholder 
comments centred on the need for enhanced Primary Care awareness of the issue, 
including GP practices, and expedited pathways toward medical treatment and 
counselling. 
 Users and community members expressed a desire for the provision of residential 
detoxification in the region with sufficient length of step down care.   
 Enhanced support with trained drug counselors, clear service pathways and the need for 
youth specific and expedited routes to treatment when the young person indicates a 
desire to stop are required. 
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Chapter Seven: Recommendations for Policy and Practice 
 
The research highlighted the concerning rapid development of tolerance, habit forming regular 
use and experience of acute withdrawal symptomatologies in users and related negative impact 
on families and communities. The study whilst localised and small-scale, highlights the need for 
further development of primary care and clinical awareness and appropriate responses, 
alongside the expedited inter-agency service pathways for drug counselling, crisis support and 
expedited medical treatment and detoxification intervention for young users and their families. 
Users seeking help and patients on admittance need to be monitored for withdrawal and with 
significant symptoms rapidly managed (Levin et al. 2010). Community efforts to act as medium 
for family support and education, schools education, harm reduction and the dissemination of 
information on available detoxification care pathways are also deemed vital in the early 
identification of trends in use, misuse and dependence, and the support of individuals requiring 
help.  
 
The following key policy and practice recommendations were generated; 
 
Policy 
16. Based on current research findings of the harmful nature of “Herbal” products, request 
clarification from the Minister with responsibility for Drugs on current Legal Status with 
a view to disseminating locally to facilitate arrests and prosecutions under recently 
amended Misuse of Drugs Act 1977-2015.  Advocate for a further review of legislation on 
harmful psychoactive substances if required. 
17. Review current cross-border policing approaches to address “Cross Border Drug 
Tourism” in the area.   
18. Review Mental Health policies regarding addiction and access criteria to services when 
psychotic symptoms are deemed ‘secondary to substance misuse’. 
 
Trend Surveillance and Early Warning and Law Enforcement  
19. Establish an expert group and an early warning system regarding Novel Psychoactive 
Substances, locally, nationally and at an EU level to reduce delays in amendments to 
legislation if/when required. 
20. Increase localised monitoring and surveillance of user trends, as it relates to existing 
products, new products, dealer networks and internet sourcing. 
21. Continue with CCTV surveillance in local areas. 
 
Education and Prevention 
22. Consult with Primary and Secondary schools locally to establish what supports are 
required to deliver SPHE and/or drug education programs to include Novel Psychoactive 
Substances, synthetic cannabinoid’s and/or emerging trends.  
23. Design and implement harm reduction activity presenting information on products, 
contents, dangers of use, overdose prevention and management, and detoxification 
referral for users, and for families in high risk communities. Incorporate Traveller 
specific elements. 
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Training  
24. Conduct training needs analysis for front line staff (i.e. TUSLA, Primary Care, GP, Gardai 
etc.) to establish current levels of drugs education, brief intervention skills, ASIST and 
referral pathways to identify gaps in existing knowledge and skills.   
25. Consult with agencies (i.e. Monaghan ETB, NE-RDATF) to deliver Community Addiction 
courses that work to reduce stigma associated with addiction. 
26. Consult with agencies regarding addiction specific training and employment initiatives 
i.e. DSP Drug specific C.E. Schemes. 
 
Clinical Responses 
27. Review current protocol surrounding pharmacological intervention for withdrawal 
symptoms associated with SCB presentations to ensure evidence based responses. 
28. Develop interagency shared care planning for crisis presentations at Accident and 
Emergency and health service level, with expedited access, adequate follow-up and 
supports on discharge. 
 
Youth Specific Responses 
29. Provide additional resources to develop youth specific addiction responses, including 
age appropriate in-patient detoxification and step-down facilities, adolescent counselling 
service and assertive youth outreach worker to identify and deliver early intervention 
initiatives. 
30. Increase local sports partnership activity in areas where youth leisure boredom is high. 
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Appendices 
 
Criteria for Substance Dependence 
 
Substance dependence is defined as a maladaptive pattern of substance use leading to clinically 
significant impairment or distress, as manifested by three (or more) of the following, occurring any 
time in the same 12-month period: 
 
1. Tolerance, as defined by either of the following: 
(a) A need for markedly increased amounts of the substance to achieve intoxication or the 
desired effect 
or 
(b) Markedly diminished effect with continued use of the same amount of the substance. 
 
2. Withdrawal, as manifested by either of the following: 
(a) The characteristic withdrawal syndrome for the substance or 
(b) The same (or closely related) substance is taken to relieve or avoid withdrawal symptoms. 
3. The substance is often taken in larger amounts or over a longer period than intended. 
4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 
5. A great deal of time is spent in activities necessary to obtain the substance (such as visiting 
multiple doctors or driving long distances), use the substance (for example,chain-smoking), or 
recover from its effects. 
6. Important social, occupational, or recreational activities are given up or reduced because of 
substance use. 
7. The substance use is continued despite knowledge of having a persistent physical or 
psychological problem that is likely to have been caused or exacerbated by the substance (for 
example, current cocaine use despite recognition of cocaine-induced depression or continued 
drinking despite recognition that an ulcer was made worse by alcohol consumption). 
 
DSM-IV criteria for substance dependence include several specifiers, one of which outlines 
whether substance dependence is with physiologic dependence (evidence of tolerance or 
withdrawal) or without physiologic dependence (no evidence of tolerance or withdrawal). In 
addition, remission categories are classified into four subtypes: (1) full, (2) early partial, (3) 
sustained, and (4) sustained partial; on the basis of whether any of the criteria for abuse or 
dependence have been met and over what time frame. The remission category can also be  used 
for patients receiving agonist therapy (such as methadone maintenance) or for thoseliving in a 
controlled, drug-free environment. 
 
Source: Cited directly from the American Psychiatric Association. Diagnostic and Statistical 
Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association, 
2000. 
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Harm Reduction Leaflet 
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Consent Form 
 
Please complete this form after you have listened to an explanation about the research. 
 
Thank you for considering taking part in this research. The person organising the 
research must explain the project to you before you agree to take part.  If you have any 
questions arising from the explanation already given to you, please ask the researcher 
before you decide whether to join in. You will be given a copy of this Consent Form to 
keep and refer to at any time. 
 
 
I understand that if I decide at any time before the interview that I no longer wish to 
participate in this project, I can notify the researcher involved and withdraw from it 
immediately without giving any reason.  
 
 
 
I understand that I can ask for my interview data to be withdrawn from the study any 
time before the summary findings are published in the final report. 
 
I consent to my interview being audio recorded. 
 
 
I understand that confidentiality and anonymity will be maintained and my 
identity will not feature in any publications 
 
 
 
Participant’s Statement: 
I agree that the research project named above has been explained to me to my 
satisfaction and I agree to take part in the study. I understand what the research study 
involves. 
Signed      Date 
 
 
Investigator’s Statement: 
Confirm that I have carefully explained the nature, demands and any foreseeable risks 
(where applicable) of the proposed research to the participant. 
Signed      Date
Yes No 
  
Yes No 
  
Yes No 
  
Yes No 
  
Please tick 
or initial 
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Severity of Dependence Scales (SDS) 
 
Circle the answer that best applies to how you have felt about your use of ‘Herbal’ over the last 
twelve months.   
 
 
1. Did you ever think your use of ‘Herbal’ was out of control?  
 
Never or almost never 0 
Sometimes 1 
Often 2 
Always 3  
 
 
2. Did the prospect of missing ‘Herbal’ make you very anxious or worried? 
 
Never or almost never 0 
Sometimes 1 
Often 2 
Always 3  
 
 
3. How much did you worry about your use of ‘Herbal’?  
 
Not at all 0 
A little 1 
Often 2 
Always or nearly always 3 
 
 
4. Did you wish you could stop?  
 
Never or almost never 0 
Sometimes 1 
Often 2 
Always 3  
 
 
5. How difficult would you find it to stop or go without ‘Herbal’? 
 
Not difficult at all 0 
Quite difficult 1 
Very difficult 2 
Impossible 3 
 
 
 SCORE____ 
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SDS: Interpretation of Scores 
 
Originally developed for assessing psychological dependence on heroin, studies have indicated 
that the SDS is a valuable tool for assessing psychological dependence on other illicit drugs. The 
research to date, has suggested cut-offs for measuring psychological dependence on various 
illicit drugs, as indicated below.  
 
 
 
 
Amphetamines   
 
 
SDS Screener has been used in a previous study to distinguish between casual and 
dependent users of Herbal (Gunderson et al., 2014). For the purposes of this study 
categorised participant score of 7 and above in the ‘dependent’ user category, and 
those under 7 in the ‘recreational user’ category.  
 
 
Cannabis & 
Benzodiazepines  
  
1.1.1.1.1.1.1 H
e
r
o
i
n 
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Interview Questions 
 
Age  
Gender 
Highest level of education 
Employment status 
Marital status 
SDS Score 
 
What substances do you use at the moment? 
 
Can you describe your use of alcohol in the past 12 months? 
 
Can you describe your use of Cannabis in the past 12 months? 
 
Can you describe your use of ‘Herbal’ in the past 12 months? 
 
Why do you use ‘Herbal’? 
Prompts (legal high, friends, cannabis replacement, quality of high, relieve irritability associated 
with cannabis withdrawal, for drug testing evasions/avoiding positive urine screens) 
 
How much do you use?  
Prompts Initial dose, redose within episode 
 
How does ‘Herbal’ compare to Cannabis?  
 
Do you need to use the same amount for a similar high? 
 
How often do you use ‘Herbal’? 
 
Do you use any other substances when taking ‘Herbal’? 
 
How much do you spend per week on ‘Herbal’? 
 
Do you plan your use of ‘Herbal’? 
 
Where do you use ‘Herbal’ and with whom? 
 
Can you describe your first experience of ‘Herbal’? 
 
Can you describe your use of ‘Herbal’ after your first time? 
 
How do you take ‘Herbal’? 
Prompt (vaporised, bong, rollup, pipe); Mixed with tobacco 
 
Can you describe the effect when you take ‘Herbal’? 
Prompts (feelings, time distortion, altered perceptions) 
How long does the effect take to come on, and how long does one dose last?  
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Do you redose? What is the longest time you have taken ‘Herbal’ over? 
 
Can you describe negative effects  you have experienced when using ‘Herbal’?  
Prompts (hunger, headache, tachycardia and respiratory difficulties, Nausea and dizziness , Fear 
and paranoia, Dehydration and dry mouth, Memory impairment, Muscle tension and pain, Ghost 
sensations, Spasms and cramps, Red eyes , Fever, anxiety, chest palpitations, panic, fatigue, nausea, 
vomiting, trouble thinking, body pain) 
How do you deal with overdose? 
 
What are the effects of ‘Herbal’ after the ‘Herbal’ episode? 
Prompts (depression, psychosis, depression, suicidal ideation Sluggish and dull, Hangover, Tired, 
Dehydration and dry mouth, Headache, Confusion, Disconnected and emotionally numb , Nausea 
and dizziness , difficulty concentrating, Memory impairment) 
 
Have you felt the effect of ‘Herbal’ decrease over time and needed to increase the dose? 
 
Have you ever felt withdrawal symptoms from ‘Herbal’? 
Prompts Withdrawal and dependence, Memory impairment, Mood swings, diisconnected and 
emotionally numb Sleeping problems, Loss of appetite , Sweating , Sluggish and dull, Rashes and 
acne, Nausea and dizziness  
 
Have you ever tried to stop but couldn’t? 
 
 
Are you aware of the health consequences of using ‘Herbal’? 
 
 
Where would you go for help if you needed it? 
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Consent Form 
 
Please complete this form after you have listened to an explanation about the research. 
 
Thank you for considering taking part in this research. The person organising the 
research must explain the project to you before you agree to take part.  If you have any 
questions arising from the explanation already given to you, please ask the researcher 
before you decide whether to join in. You will be given a copy of this Consent Form to 
keep and refer to at any time. 
 
 
I understand that if I decide at any time before the interview that I no longer wish to 
participate in this project, I can notify the researcher involved and withdraw from it 
immediately without giving any reason.  
 
 
 
I understand that I can ask for my interview data to be withdrawn from the study any 
time before the summary findings are published in the final report. 
 
I consent to my interview being audio recorded. 
 
 
I understand that confidentiality and anonymity will be maintained and my 
identity will not feature in any publications 
 
 
 
 
Participant’s Statement: 
I agree that the research project named above has been explained to me to my 
satisfaction and I agree to take part in the study. I understand what the research study 
involves. 
Signed      Date 
 
 
Investigator’s Statement: 
Confirm that I have carefully explained the nature, demands and any foreseeable risks 
(where applicable) of the proposed research to the participant. 
Signed      Date
Yes No 
  
Yes No 
  
Yes No 
  
Yes No 
  
Please tick 
or initial 
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Interview Themes: Service Stakeholder  
 
Use of synthetic cannabinoids as recent trend 
 
Profile of users 
 
Sourcing networks 
 
Impact of use on individual, family and community  
 
Service responses, needs and strategies for management  
 
Drug education and harm reduction 
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